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ABSTRACT 
The antigenic regions of a-momorcharin (aMMC) has been 
determined by expression of full-length and modified forms of the 
aMMC cDNA in E, coli. The full-length recombinant aMMC was 
purified and found to be biologically active. Other forms of the 
A 
recombinant DNA were constructed and functionally expressed. 
Three distinct epitopic regions on the aMMC molecule were 
revealed in our study. These regions were analysed and compared 
with the 3-dimensional structure of aMMC. One of the regions was 
found to be located at the opening of the proposed active site cleft 
believed to be associated with ribosome inactivation. Our results 
showed that binding of a monoclonal aMMC antibody to this region 
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CHAPTER 1 INTRODUCTION 
Ribosome-inactivating proteins (RIPs) are widely distributed in 
the plant kingdom (Stiipe and Barbieri，1986). The action of these 
proteins is characterized by their ability to inactivate eukaryotic 
ribosomes and preventing the 60S subunit to bind to elongation factor 
2，consequently protein synthesis is inhibited (Stirpe et al； 1992). 
Most RIPs are frequently found as single polypeptide chains (Type 1)， 
but some contain two chains (Type 2)，one with enzymic activity and 
the other with galactose binding property. The two chains are linked 
by hydrophobic interaction and disulfide bridge. Type 2 RIPs can 
enter cells readily through the interaction of their lectin moiety with 
the cell membrane, and so always are potent toxins. On the other 
hand, type 1 RIPs are less toxic because they do not possess a lectin 
domain for binding onto cell surface (Stirpe et aL, 1992). 
RIPs are similar in their chemico-physical properties, amino 
acid sequences and enzymic activities (Ng et aL, 1992). Most type 
1 RIPs are glycoproteins, with molecular weights between 26 and 32 
KD, and have alkaline isoelectric points greater than 9 (Stirpe et aL, 
1 
1992). 
Interest in RIPs is increasing as they can be used as the toxic 
moiety in immunotoxins for the treatment of several important human 
diseases including cancer (Lambert et al； 1988). Some RIPs are 
reported to have antiviral activity against animal and plant viruses 
(Foa-Tomasi et al； 1982). Recently, it has been shown that some 
type 1 RIPs including pokeweed antiviral protein (Kung et al., 1990), 
MAP-30 (Lee-Huang et al., 1990), TAP-29 (Lee-Huang et al, 
1991a)，GAP-31, DAP-30 and DAP-32 (Lee-Huang et al； 1991b), 
trichosanthin and a-momorcharins (Lifson et al” 1988; McGrath et 
al； 1989，Shaw et al” 1994) are directly active against fflV-1. 
Among them, trichosanthin has been used in clinical trial for AIDS 
therapy (Byers et al； 1990; Kahn et al., 1990; McGrath et al” 1989). 
1.1 BRIEF DESCRIPTION OF MOMORDICA CHARANTIA 
Momordica charantia is a Chinese medicinal plant. The fruit 
and seed extracts of Momordica charantia have been used in China 
for centuries in the treatment of virus and cancer related diseases (Li, 
2 
1596; Jilka et al., 1983). In recent years, several bioactive proteins 
have been isolated from the seeds of this plant. Some examples are 
MAP-30 (Lee-Huang et al, 1990)，MC inhibitors and momordin 
(Falasca et cd., 1982)，and a-and 6-momorcharins (Yeung et al； 
1986). These proteins belong to single-chain ribosome-inactivating 
proteins (Type 1 RIPs), which are able to inactivate eukaryotic 
ribosomes leading to the inhibition of protein synthesis (Barbieri et 
al., 1980). Among these proteins, a-momorcharin (aMMC) was 
found to possess a variety of biological activities including mid-term 
abortion (Chan et al., 1984), inhibition of tumour growth (Yeung et 
al； 1988) and suppression of immunological responses (Leung et al., 
1987). Recently, aMMC has been shown to have anti-HIV properties 
(Lifson et al； 1988). 
1.2 TOXICITY OF RIPs AND THEIR POTENTIAL USES IN THE 
TREATMENT OF AIDS 
The cytotoxicity profiles of trichosanthin and a-momorcharin 
have been reported (Tsao et al； 1990). Unlike most anti-cancer drugs 
such as cisplatin, methotrexate and 5-fluorouracil, which interfere 
3 
with DNA metabolism, cytotoxcity of RIPs is mainly due to 
inhibition of cellular protein synthesis (Tsao et al., 1990). Generally, 
type 1 RIPs display relatively low toxicity to most intact cells with 
the exception of macrophages (Stirpe and Barbieri，1986). This 
characteristic of RIPs is of interest to many researchers and leads to 
the use of RIPs for treatment of AIDS. Cells such as macrophages 
and monocytes expressing CD4 on their surface are susceptible to 
HIV infection (Dalgleish et al., 1984). The infected macrophages are 
capable of expressing the HIV surface antigen which may interfere 
and fuse with CD4+ T-cells, leading to destruction of the T-cells 
(Crowe et al•，1987). Some nucleoside analogues such as AZT are 
able to arrest HIV replication by inhibition of the viral reverse 
transcriptase (Broder, 1987). Since reverse transcriptase is required 
at early stages of viral infection, these drugs are effective only for 
new infections. Once viral infection is established, the viral 
replication is carried out using host cell enzymes, these reverse 
transcriptase inhibitors would have little effects on viral replication 
at this point (Pemo et al； 1988). Unlike the above drugs, 
trichosanthin and a-momorcharin have been reported to selectively 
inhibit HIV replication and proliferation at later stages in the HIV-
infected human T-cells and mononuclear phagocytic lineage cells in 
4 
vitro (Lifson et al.，1988). The effective concentration of TCS and 
aMMC for the selective inhibition of HIV was found to be between 
0.01 to 3.0 |Lig/ml, which did not significantly reduce the viability of 
non-infected cells, indicating that certain RIPs can be used as a new 
agent to treat HIV infection (Lifson et al； 1988; Kahn et al； 1990). 
Not all RIPs are potential anti-HIV agents. Wachinger (1993) 
has studied the anti-HIV effects of certain RIPs and found that 
gelonin and ricin did not have selective effects in HIV-infected T_ 
lymphoma cells, whereas TCS and bryodin (an RIP isolated from 
Bryonia cretica of Cucumbitaceae family) were effective in the same 
dose range. This observation suggests that there may be some 
alternative mechanism accounting for HIV inhibition other than the 
general ribosome-inactivating properties. 
The use of RIPs in anti-HIV treatment is not perfect. Some 
AIDS patients when treated with a TCS preparation, GLQ223, 
experienced a significant neurological toxicity with clinical features 
resembling acute disseminated encephalomyelitis (Pinching 1990). 
These adverse effects would develope approximately 24 hr after a 
single injection of 36 |Lig/Kg of GLQ223. Recently, MAP-30 isolated 
5 
from extract of MC was found to possess anti-HIV activity but have 
a much lower cytotoxicity as compared to GLQ223 (Lee-Huang et 
al； 1990). 
1.3 GENERAL MECHANISM OF ACTION OF RIPs 
The molecular mechanism in the action of RIPs was first 
elucidated by Endo and his collaborators in 1987 (Endo et al., 1987). 
It is now widely accepted that plant and some bacterial RIPs, such 
as trichosanthin and ricin A-chain, are N-glycosidases which act by 
cleaving the glycosidic bond between an adenine and a ribose at 
nucleotide A-4324 of the 28S rRNA (Zhang and Liu, 1992). Fungal 
RIPs such as a-sarcin are RNases cleaving the phosphodiester bond 
between G-4325 and A-4326 of the same rRNA (Endo and Wool, 
1982). After cleavage, a dramatic conformational change is 
introduced to the 28S rRNA, rendering it unable to bind the GTP-
dependent elongation factor 2 (EF-2). Because of this, protein 
synthesis is halted. 
Some RIPs are reported to have DNase activity. Diphtheria 
6 
toxin was found to be able to cleave supercoiled，close-circular DNAs 
into nicked-circular, linear, and acid-soluble DNA fractions 
(Nakamura and Wienieski, 1990). Alpha- and 6-momorcharins were 
also reported to have DNase activity (Go et al； 1992). However, the 
observation of DNase activity in other RIPs is still controversal 
(Johnson, 1990). 
•� 
1.4 STRUCTURE OF aMMC 
Alpha-MMC isolated from natural sources is a glycoprotein 
(Yeung et al., 1986). It is a basic protein with a molecular weight of 
approximately 31,000 Da and a pi of about 9. Since aMMC and 
TCS have similar ribosome-inactivating properties and TCS is not a 
glycoprotein, glycosylation in aMMC does not appear to be essential 
for this biological activity (Yeung et al； 1988). 
The amino acid sequence of the N-terminal residues of aMMC 
has been reported (Yeung et al” 1987), and the complete sequence of 
the protein was deduced following the cloning of the aMMC cDNA 
(Ho et al； 1991) (Fig. 1.1). The aMMC cDNA consists of 1044 bp 
7 
with an open reading frame coding for the aMMC polypeptide, of 
which the first 23 amino acids are for a signal peptide and the last 10 
amino acids are for a propeptide. According to the deduced amino 
acid sequence, the mature aMMC is composed of 253 amino acids 
with a calculated molecular weight of approximately 28000 Da. 
The primary sequences of most RIPs are very similar (Fig. 1.2). 
Funatsu et aL (1991) have compared and analysed the amino acid 
sequences of eleven RIPs and found that thirteen amino acids in ricin 
A-chain are highly conserved. They are Tyr-21, Phe-24, Arg-29, Tyr-
80, Tyr-123, Gly-144, Ala-165，Glu-177, Ala-178, Arg-180, Glu-208, 
and Trp-211, corresponding to their relative positions on ricin A. 
These residues are believed to be crucial either in stabilizing the 
conformation of the molecule or in being responsible for the ribosome 
inactivating properties. 
8 
Met Ser Arg Phe Ser Val Leu Ser Phe Leu lie 11 
1 AAT TCC CTG TGA AAC ATG AGT AGA TTC TCA GTT CTC TCA TTT CTA ATT 48 
-signal sequence - N-terminal start 
12 Leu Ala lie Phe Leu Gly Gly Ser lie Vel Lys Gly Asp Val Ser Phe 27 
49 CTC GCA ATC TTC CTT GGA GGT TCT ATT GTC AAA GGC CAT GTT AGC TTT 96 
28 Arg Leu Ser Gly Ala Asp Pro Arg Ser Tyr Gly Met Phe lie Lys Asp 43 
97 CGT TTG TCG GGT GCT GAT CCT AGA TCC TAT GGG ATG TTC ATC AAA GAT 144 
4 4 Leu Arg Asn Ala Leu Pro Phe Arg Glu Lys Val Tyr Asn lie Pro Leu 59 
145 TTG AGG AAT GCT CTT CCA TTT CGA GAG AAA GTG TAG AAT ATA CCT CTC 192 
60 Leu Leu Pro Ser Val Ser Gly Ala Gly Arg Tyr Leu Leu Met His Leu 75 
193 TTA CTT CCT TCC GTT TCA GGA GCA GGA CGA TAG TTA CTA ATG CAT CTC 240 
76 Phe Asn Tyr Asp Gly Lys Thr lie Thr Val Ala Val Asp Val Thr Asn 91 
241 TTC AAT TAG GAC GGA AAA ACC ATC ACA GTG GCC GTA GAT GTA ACA AAC 288 
92 Val Tyr lie Met Gly Tyr Leu Ala Asp Thr Thr Ser Tyr Phe Phe Asn 107 
289 GTT TAG ATT ATG GGC TAT CTT GCC GAT ACA ACA TCC TAG TTT TTT AAC 336 
108 Glu Pro Ala Ala Glu Leu Ala Ser Gin Tyr Val Phe Arg Asp Ala Arg 123 
337 GAG CCT GCT GCT GAA TTA GCT TCT CAA TAT GTA TTC CGA GAC GCT AGG 384 
124 Arg Lys lie Thr Leu Pro Tyr Ser Gly Asn Tyr Glu Arg Leu Gin lie 139 
385 AGG AAG ATT ACA CTT CCA TAT TCT GGC AAT TAG GAA AGG CTT CAA ATT 432 
140 Ala Ala Gly Lys Pro Arg Glu Lys lie Pro lie Gly Leu Pro Ala Leu 155 
433 GCT GCA GGC AAG CCA AGA GAA AAA ATC CCC ATT GGA CTC CCA GCG TTG 480 
156 Asp Ser Ala lie Ser Thr Leu Leu His Tyr Asp Ser Thr Ala Ala Ala 171 
481 GAT AGT GCA ATA AGC ACC TTG CTG CAT TAT GAC TCC ACA GCT GCC GCT 528 
172 Gly Ala Leu Leu Val Leu lie Gin Thr Thr Ala Glu Ala Ala Arg Phe 187 
52 9 GGG GCA CTG CTT GTA CTC ATT CAG ACC ACT GCG GAG GCT GCG AGA TTT 576 
188 Lys Tyr lie Glu Gin Gin lie Gin Glu Arg Ala Tyr Arg Asp Glu Val 203 
577 AAG TAT ATT GAG CAA CAA ATT CAA GAA AGA GCT TAC AGA GAC GAG GTC 624 
204 Pro Ser Leu Ala Thr lie Ser Leu Glu Asn Ser Trp Ser Gly Leu Ser 219 
625 CCG AGT CTA GCA ACT ATA AGT TTA GAA AAC AGT TGG TCT GGT CTC TCC 672 
220 Lys Gin lie Gin Leu Ala Gin Gly Asn Asn Gly lie Phe Arg Thr Pro 235 
673 AAA CAA ATC CAG TTA GCG CAG GGC AAT AAT GGA ATA TTT AGA ACT CCT 720 
236 lie Val Leu Val Asp Asn Lys Gly Asn Arg Val Gin lie Thr Asn Val 251 
721 ATT GTG CTT GTG GAT AAC AAA GGA AAT CGA GTC CAG ATA ACC AAC GTT 768 
252 Thr Ser Lys Val Val Thr Ser Asn lie Gin Leu Leu Leu Asn Thr Arg 267 
769 ACT TCA AAA GTT GTA ACC TCC AAC ATA CAG TTA TTG TTA AAC ACA CGA 816 
268 Asn lie Ala Glu Gly Asp Asn Gly Asp Val Ser Thr Thr His Gly Phe 283 
817 AAT ATT GCA GAG GGT GAC AAC GGC GAT GTT TCT ACA ACA CAT GGC TTT 864 
C-terminal 
284 Ser Ser Tyr *** 
865 TCG AGC TAC TAG AAT GCC CTA AAG ATG GTG AAT ATG GAA AAT ATG TTA 912 
913 CAA CTT TGA GGT AGC AAC TAC AAC TCC ACT TGA AGA ATA ATG TTC CTT 960 
961 CCA TGC TTT GTA AGT GTG TTT TAT TTC CCT TTA TCA ATA AAA AAA TGT 1008 
1009 GGA ACC TTT TAA TGC TTT CAA AAA AAA AAA AAA AAA 
Fig. 1.1 The cDNA and the deduced amino acid sequence of aMMC (Ho et al, 1991) 
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Qf-MMC DVSFRLS GADPRSYGMFIKDLRNALPFREKV YNIPLL LPSVSGAGRYLLM 
TCS DVSFRLS GATSSSYGVFISNLRKALPNERKL YDIPLL RSSLPGSQRYALI 
Ricin A IFPKQYPIINFTTA GATVQSYTNFIRAVRGRLTTGADVRHEIPVLPNRVGLPINQRFILV 
Abrin A EDRPI KFSTE GATSQSYKQFIEALRERLRGGL I HDIPVLPDPTTLQERNRYITV 
MAP APTLETIASLD LNNPT TYLSFITNIRTKYADKTEQ CTIQKI SKTF TQRYSYI 
60 70 80 90 100 
a-MMC HLFNYDGKT ITVAVDVTNVYIMGYLADTT SYFFNEPAAEL ASOYVF RDAR 
TCS HLTNYADET IS^IDWNVYIMGYRAQDT SYFFNEASATE A A K W F KDAM 
Ricin A ELSNHAELS VTLALDVTNAYWGYRAGNS AYFFHPDNQEDAEAITHLF TDVQ 
Abrin A ELSNSDTES lEVGIDVTNAYWAYRAGTQ SYFLRDAPSS ASDYLF TGTD 
MAP DLIVSSTQK ITLAIDMADLYVLGYSDIANNKGRAFFFKDVTEAV ANNF FPGATG 
110 120 130 140 150 
Oj-MMC RKITLPYSGNYERLOIAAGKPREKIPIGLPALDSAISTLLHY DSTAA AGALLV 
TCS Ri^TLPYSGNYERLOTAAGKliiNIPLGLPALDSAITTLFYY NANSA ASALMV 
Ricin A SiYTFAFGGNYDRLEQLAGNLiiNliLGNGPLEEAISALYYYSTGGTQLPTLARSFII 
Abrin A QH SLPFYGTYGDLERWAHQSRQQIPLGLQALTHGIS FF SGGNDNEEKARTLIV 
MAP TNRIKLTFTGSYGDLEKNGG LRKDNPLGIFRLENSIVNIYGK AGDVKKQ ALFFLL 
160 170 180 190 200 
OF-MMC LIQTTAEAARFKYIEQQIQERAYRD EVPSLATISLENSWSGLSKOIOLAOGNNGIF 
TCS LIQS�siX^YiFIEOOIGKivDKT FLPSLAIISLENSWSALSKQIQIASTNNGQF 
Ricin A CIQMISEAARFQYIEGEMRTRIRYNRRSAPDPSVITLENSWGRLSTAIQE SNQGAF 
Abrin A IIQMVAEAARFRYISNRVRVSIQTGTAFQPDAAMISLENNWDNLRG VQE SVQDTF 
MAP AIQMVSEAARFKYISDKIPSEKYEE VTVDEYMTALENNWAKLSTAVYNSKPS TTT 
210 220 230 240 250 260 
CX-MMC RTPIVLVDNKGNRVOITNVTSKWTSNIQLLNTRNIAEGDNGDVSTTHGFSSY 
TCS ESiv^INAQNQi^TiTNVDAGWTSNIAIiLLNRNMA 
Ricin A ASPIQLQRRNGSicFSVYDVS ILIPIIALMVYRCAPPPSSQF 
Abrin A PNQVTLTNIRNEPVIVDSLSH PTVAVLALMLFVCNPPN 
MAP ATKCQLATSPVTIS PWIFKTVEEIKLVMGLLKSS 
Fig. 1.2 Comparison of the sequence of aMMC with some ribosome-inactivating 
proteins. aMMC (Ho et al, 1991); TCS (Shaw et al, 1991); ricin 
A chain (Lamb et al, 1985); abrin A chain (Funatsu et al., 1988); 
MAP (Marabilis anti-viral protein, Habuka et al； 1989). The highly 
conserved residues are indicated in bold letters. 
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It is of interest that the primary sequence of aMMC is highly 
homologous to that of TCS, although they are isolated from quite 
different sources, viz, aMMC from seeds of Momordica charantia 
and TCS from the root tuber of Trichosanthes kirilowii. Most of the 
homologous regions of these two proteins are found in the N-terminal 
half of their sequences. 
Kubota et al. (1986) have analysed the secondary structures of 
aMMC, 6MMC and TCS and found that all these proteins contain 
about 30% a-helix, 40-60% B-sheets, but no 6-tums. Collin et al. 
(1990) have proposed a model for the 3-D structure of TCS by energy 
minimization method using a set of known X-ray diffraction data of 
ricin A-chain. Direct X-ray diffraction analyses on TCS (Gao et a/” 
1993; Pan et al., 1993) and aMMC (Feng et al•，1990; Dong, 1993) 
have been reported. With the help of the 3-D model of aMMC, 
Dong (1993) proposed that Tyr-70, Tyr-111, Glu-160, Arg-163 and 
Tip-192 of aMMC are located on the surface of the active site cleft 






Fig. 1.3 Three-dimensional structure of aMMC. 
Some amino acid residues in the proposed active 
site cleft are indicated. 
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1.5 ANTIGENICITIES OF aMMC, 6MMC and TCS 
The antigenicities of the abortifacient proteins aMMC, 6MMC 
and TCS have been studied (Leung et al,, 1987). In general, these 
proteins are very strong immunogens. Zheng et aL (1991) have found 
that the IgE titers in BALB/C and C57 mice were significantly 
increased after intraperitoneal injections of these proteins. The 
antigenicity was highest in 6MMC, less in aMMC and TCS. 
A variety of clinical applications of TCS have been reviewed 
(Wang et al； 1986). The roots of Trichosanthes kirilowii has been 
used in Chinese traditional medicine for more than a thousand years 
to induce abortion. TCS is now used in China to interrupt normal or 
ectopic pregnancies. It is also used in the therapy of choriocarcinoma 
(Wang et al” 1986). Besides trichosanthin, a- and B-MMC are known 
to have similar abortifacient and anti-tumour activities (Yeung et aL, 
1988). Recently, the anti-HIV activities of these proteins have been 
observed (McGrath et al., 1989). 
The common problem of using these abortifacient proteins as 
therapeutic agents is their antigenicities and the side effects, 
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especially when needed for prolonged and repeated use. It was found 
that most RIPs are distinct in their antigenicity. Ng et al. (1993) have 
analysed and compared the immuno-relatedness of seven RIPs 
including TCS, BTCS, aMMC, 6MMC, MCC, LFC and MAP using 
ELISA. Basically, they found that antisera raised from a particular 
RIP would exhibit the highest reactivity against its homologous 
antigen, although some degree of cross-reactivity was also observed. 
This suggests that alternate use of different RIPs with similar 
therapeutic properties is a way to minimize the induction of 
hypersensitivity upon repeated use of the same protein. 
1.6 IMMUNOSUPPRESSIVE PROPERTIES OF THE 
ABORTIFACIENT PROTEINS aMMC, 6MMC AND TCS 
In contrast to being a good immunogen，the abortifacient 
proteins aMMC, 6MMC and TCS are also immunosuppressive. 
Zheng et al (1991) have observed that the increased IgE levels in 
mice in response to a single ovalbumin injection was significantly 
suppressed by priming the mice with these abortifacient proteins one 
day before the antigen challenge. The maximum suppression was 
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observed after 28 days, and was found to be more effective in the 
male. They also found that these proteins effectively inhibited 
transformations of T-lymphocytes induced by phytohaemagglutinin 
and B-lymphocytes induced by lipopolysaccharide. The 
immunosuppressive effects of these proteins may be due to their high 
toxicity to macrophages possibly mediated by their RIP activity 
(Leung et al” 1987). 
1.7 OBJECTIVES OF OUR STUDY 
Alpha-MMC and many other type 1 RIPs are highly 
homologous in sequence and share similar biological fiinctions. 
However, the antigenicities of these proteins are quite distinct (Ng et 
al； 1992). An antiserum raised against one RIP may not cross-react 
with another. The molecular basis for the biological activity appears 
to be related to the ribosome-inactivating properties, but the 
molecular basis for their common and/or varied antigenicities is still 
unknown. 
It is of interest to determine the epitope segments of different 
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RIPs. Since the tertiary structure of aMMC is known, the 
determination of the epitope segments of this molecule can then be 
easily correlated with its 3-D structure. Such a study would provide 
more detailed information of the antigenic properties of this protein 
and facilitate research on the diverse immunological effects of RIPs 
through modification of these segments by protein engineering. 
The structure-function relationship of a macromolecule can be 
studied by chemical modification. For example, Olsnes and Saltvedt 
(1976) have observed a conformational change in ricin A chain when 
the whole ricin molecule was reduced by B-mercaptoethanol. The 
detectable epitopes of ricin A chain on the intact ricin were no longer 
evident on the free A chain. Watanabe and Funatsu (1986) also have 
modified nine arginine residues of whole ricin with 1,2-
cyclohexanedione and found that the modification has little effect on 
the toxicity and cytoagglutinating activity of ricin, suggesting that 
these arginine residues are not involved in these activities. 
Unfortunately, these chemical methods can only modify those reactive 
residues on the surface of the molecule. The reactions frequently 
require a non-aqueous solvent environment which may be problematic 
to many sensitive proteins. The residues are modified according to 
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their chemical nature rather than their positional differences. These 
methods are therefore less specific and were not adopted in our study. 
In addition to chemical modification, the nature of a protein 
molecule can also be studied by fragmentation. To obtain fragments, 
the protein can be digested by certain proteolytic enzymes such as 
trypsin, pepsin or pronase (Lugnier et al； 1976). However, it was 
found that some enzymes are unable to cleave a particular protein 
and it is difficult to obtain specific small fragments (Yoshitake et al； 
1979). If the protein sequence is known, the use of synthetic peptides 
defining the sequences of interest is an alternative method. Since the 
antigenic sequences of aMMC are unknown, the use of randomly 
generated synthetic peptides is costly and not effective. 
The cDNA fragment of aMMC has been cloned, and the amino 
acid sequence of aMMC has been deduced (Ho et al•，1991). The 
structure and function of aMMC can be studied by expression and 
modification of the cDNA. There are several advantages in using 
bacterial expression in our study. Firstly, an adequate quantity of 
recombinant aMMC can be obtained for analytical purposes if the 
cDNA is expressed in an appropriate system. Secondly, full-length 
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and fragmented aMMC can be obtained by modification or deletion 
of the cDNA sequence. Thirdly, the amino acid sequences of the 
expressed fragments can be easily deduced from the cDNA. 
Site-directed mutagenesis of the cDNA can specifically modify 
or substitute one or more amino acids in the protein product. Since 
the epitope regions of aMMC have not been found, site-directed 
mutagenesis is therefore not suitable at this stage. Instead of 
mutagenesis, aMMC was studied by fragmentation. In the beginning 
of our study, fragmented aMMCs were generated by unidirectional 
deletion of the aMMC cDNA fUsed to the protein A gene with a 
factor Xa cleavage site in between. In addition, we have also 
constructed a chimeric protein from aMMC and TCS. The purpose 
of the former approach is to prepare a set of smaller and smaller 
aMMC fragments and determine their antigencities. The chimeric 
construct would be used to compare the antigenic properties between 
aMMC and TCS. 
In the second part of our study, a method in determining 
aMMC antigenic fragments by screening a random fragment library 
was developed. This method has many advantages over unidirectional 
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deletion. In unidirectional deletion，the antigenicity of the molecule 
would decrease as the deletion progresses. To screen the antigenic 
regions, a large quantity of the deletion fragments has to be isolated 
and determined. If a protein have several epitopes, this method is not 
easy to differentiate between them. In contrast to deletion， the 
method of random screening works with the 'positive signals' rather 
than excluding them. Using this method, three distinct epitopic 
regions of aMMC have been determined. The mapping of these 
eiptopes on the 3-D structure has yielded important information on 
the surface topology of this molecule. 
�� 
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CHAPTER 2 EXPRESSION OF FULL-LENGTH 
ofMMC cDNA 
Alpha-MMC is a RIP first isolated from the seeds of 
Momordica charantia. The properties of this protein have been well 
studied. However, the isolation of this protein from a recombinant 
source has not been reported and the properties of the recombinant 
protein is unknown. In our study, the antigenic properties of aMMC 
were investigated by expressing different forms of aMMC cDNA in 
the E. coli. Before any modification is contemplated, it is important 
to express the full-length aMMC cDNA and to investigate the 
properties of the recombinant aMMC to validate our approach. It is 
known that there may be many differences between an aMMC 
expressed in E. coli versus that expressed in the native plant. The 
natural aMMC is a glycoprotein while that expressed in E. coli is not 
glycosylated. Most foreign proteins in E. coli are expressed as 
inclusion bodies and the recombinant protein has to be refolded and 
may not be biologically active. In spite of these limitations, the E. 
coli system has several advantages over the eukaryotic system. The 
genetics and physiology of E. coli are well studied. It is simple and 
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easy to control. The rapid rate of cell growth and availability of low-
cost culture conditions for E. coli make it the preferential choice as 
a host for gene expression. Therefore, we have chosen the E. coli 
expression system in our study. 
In our first experiment, the aMMC cDNA was expressed as a 
fusion protein. We use this approach because it has several 
advantages. For many small proteins or peptides, fusion proteins are 
more stable and are less subjected to proteolysis (Itakura et al., 1977). 
This would be extremely useful in stabilizing small deletion 
fragments of aMMC cDNA. The second advantage is that poor 
translation initiation due to secondary structures of mRNA can be 
avoided by substituting the initiating sequence of a efficiently 
translated fusion protein (Schoner et al； 1984). 
Staphylococcal protein A is a protein which binds to the Fc 
portion of most mammalian class G immunoglobulins (IgGs). The 
IgG binding domain B of protein A has a very strong affinity for IgG 
with a dissociation constant of 2 x 10"^  M. This permits efficient 
purification of protein A fusion by IgG affinity chromatography 
� -
(Lindmark et al•，1983). By constructing a fusion of aMMC with 
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protein A, the purification of aMMC can be performed in an IgG-
affinity column even when the aMMC chain has been modified or 
deleted partly. In view of these considerations, protein A fiision is a 
good expression system and was chosen in the beginning of our 
study. 
2.1 EXPRESSION OF aMMC cDNA AS A FUSION PROTEIN 
2.1.1 MATERIALS AND METHODS 
2.1.1.1 CONSTRUCTION OF FUSION VECTOR pRIT2T/MMC 
The protein A fusion vector pRIT2T (Fig. 2.1) was purchased 
from Pharmacia (Sweden). This vector is designed for intracellular 
expression of protein A fusion proteins mE. coli (Uhlen et al., 1983). 
Expression is controlled by the Pr promoter from bacteriophage 入， 
which can be regulated by temperature (Milman, 1987). When the 
culture is grown at a temperature of 28-30°C, the promoter is 
repressed by the repressor protein c/857 produced by the E. coli host 
having a cl gene. To induce expression, the E. coli culture is 
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transferred to a higher temperature of 38-42°C. At this temperature, 
the c/857 repressor protein is inactivated. The promoter is therefore 
turned on and the expression initiates. An outline in the construction 
of pRIT2T/MMC is illustrated in Fig. 2.2. 
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Multiple cloning sites 
Ecom 
Smal Bamm 
I r .Hindi \ 
Protein A ^ H ^ - j U ^ Sail 
^^ScrPsti 
/ \ 
/ r \EcoKW 
I pRIT2T n Protein A Terminator 
^ T 4250 bp T 
Amp^  
Fig. 2.1 Plasmid map of pRIT2T 
� 
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Primer 1 aMMC 
f \ PCR Factor Xa 
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I PUC18 based ) Ecom a M M C BamHl 
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± \ EcoRY 
X P r B PRIT2T/MMC 
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Fig. 2.2 Construction of pRIT2T/MMC 
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2.1.1.2 PREPARATION OF aMMC INSERT BY PCR 
Two primers (Fig. 2.3) flanking the mature sequence of aMMC 
cDNA were synthesized in an ABI DNA synthesizer (Applied 
Biosystems Inc., USA) and purified using OPC columns (Applied 
Biosystems, USA) according to the instructions provided by the 
manufacturer (Appendix A.3). 
Primer 1： 
EcoRl Factor Xa aMMC N-terminal 
5' CG CGG AAT TCC ATT GAA GGA AGA GAT GTT AGC TTT CGT TTG TCG GGT 3' 
Primer 2: 
BamHI aMMC C-terminal 
5' GCG CGGA TCC TTA GTA GCT CGA AAA GCC ATG TGT TGT 3' 
Fig. 2.3 Sequences of the PCR primers 1 and 2: 
In a 0.5-ml microfUge tube, the following PCR components 
were mixed: 
Double distilled water 33.5 |LI1 
lOx Reaction buffer 5 |il 
dNTP's mix, 1.25 mM each 5 |il 
Primer 1 (0.1 |LI_) 2 |il 
Primer 2 (0.1 2 |LI1 
Taq DNA polymerase (5 u/|il) 0.5 |LI1 
MMC18p8 plasmid DNA (5 ng/|il) 2 pi 
Total: 50 |il � 
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Before PCR，30 |LI1 of mineral oil were carefully layered on top 
of the mixture. PCR was carried out in a Coy Model 60 
thermocycler (USA) with 1 cycle at 94�C 5 min，50�C 2 min，72°C 
3 min; 28 cycles at 94°C 1 min, 50�C 2 min, 72�C 3 min; and 1 
cycle at 94°C 1 min, SO'^ C 2 min and 72�C 10 min. The aqueous 
layer was removed and the amplified materials were separated on a 
1.5% agarose gel. The band corresponding to the expected size of the 
aMMC cDNA (ca. 800 bp) was excised and purified by the Gene 
Clean procedure (Bio 101，USA) as described in Appendix A.2. 
2.1.1.3 CLONING OF aMMC cDNA INTO FUSION 
VECTOR pRIT2T 
One |ig of the above aMMC cDNA fragment (in 2 |al) was 
digested with EcoRL and BamHI (2 insert, 10 u EcoRI, 10 u 
BamHI, 2 |Lil lOx One-Phor-All restriction buffer (Pharmacia), 5 |al 
H2O) at 37�C for 1.5 hr. Five |Lig of the plasmid pRIT2T were 
separately digested with the same enzymes. The insert and the vector 
were precipitated by addition of 0.1 volume of 3M sodium acetate, 
pH 5.7 and 2 volumes of absolute ethanol at -20°C for 30 min. The 
27 
precipitates were washed with 300 of 70% ethanol and dissolved 
in 10 i^l TE buffer (pH 8.0). Three |LI1 of the linearized plasmid (2 
|Lig) were mixed with 5 |LI1 of insert (0.5-1 |Lig) in 2 |LI1 of lOx ligation 
buffer, 1 |Lil of T4 DNA ligase，19 |LI1 of H2O and incubated at 16°C 
for 4 to 16 hr. The entire ligation mix was used directly for 
transformation. 
2.1.1.4 TRANSFORMATION 
Compentent cells of E. coli strain N4830-1 were prepared as 
follows: A single bacterial colony was inoculated into 2 ml of SOB 
(2% Bactotryptone, 0.5% Bacto yeast extract, 10 mM NaCl，2.5 mM 
KCl, 10 mM MgCl2, 10 mM MgSC^ and shaked at 37°C overnight. 
A 0.1 ml portion of this overnight culture was mixed with 10 ml 
fresh SOB and continued to shake for 3 hr. The cells were harvested 
by centrifugation at 5000 rpm for 10 min at 4°C, and re-suspended 
in 3 ml cold TFB (100 mM KCl, 45 mM MnC1.4HA 10 mM 
CaCl2.2H20�3 mM H A C o C l � � 1 0 mM K-MES, pH 6.20). The 
suspension was centrifuged again at 5000 xg for 10 min. The pellet 
was suspended in 0.8 ml cold TFB. To prepare competent cells, 28 
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|Lil of DnD (1 M DTT, 10 mM potassium acetate, 90% v/v DMSO) 
were added and mixed immediately. The cells were incubated on ice 
for 10 min，then another 28 |LI1 of DnD were added. The cells were 
incubated on ice for further 10 min. For transformation, a 20-|LI1 
aliquot of competent cells was mixed with 1 |LI1 of the ligation mix or 
a positive plasmid control (50-200 ng) and incubated on ice for 30 
min in microfuge tubes. The cells were then heat-shocked at 42°C for 
exactly 50 sec, and put on ice for 1 min. 
The transformed bacteria were mixed with 80 |LL1 of SOC (20 
mM glucose in SOB) and incubated at 37°C for 1 hr to express the 
appropriate antibiotics resistance, and streaked on an LB agar plate 
containing 50 |Lig ampicillin/ml using a turn-table. 
2.1.1.5 DNA SEQUENCING 
DNA sequencing was carried out according to the method of 
Sanger et al. (1977) with modifications. ^^S-dCTP was purchased 
from Amersham (UK). T7 DNA Sequencing Kit was purchased from 
Pharmacia (Sweden) (Appendix A.l). The sequencing primer (Fig. 
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2.4) was synthesized using an ABI DNA synthesizer (Appendix A_3). 
5' TGA TGC ACA AGC ACC AAA AGC TG 3' 
Fig. 2.4 Protein A sequencing primer (23 bp) 
2.1.1.6 EXPRESSION OF PROTEIN A-aMMC FUSION cDNA 
A single colony of E. coli N4830-1 (Pharmacia, Sweden) 
transformed with aMMC cDNA was inoculated and shaken in 2 ml 
of LB containing 50 |Lig ampicillin/ml at 37°C overnight. The culture 
was then diluted 100 fold in 2 ml of fresh LB containing the same 
antibiotics and continued to shake for 3 hr or until OD6oo=0.5. To 
induce expression, the culture was transferred to a 40°C water bath 
and shaked for 1.5 hr. Cells were harvested by centrifugation at 5000 
xg 5 min, and suspended in 50 |il of SDS-PAGE loading buffer. The 
suspension was sonicated 3x15 sec on ice, boiled for 5 min in a water 
bath, and centrifuged at 5000 xg for 5 min. The preparation was then 
for use of SDS-PAGE and Western transfer analysis. 
� 
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2.1.1.7 PREPARATION OF FUSION aMMC FOR AFFINITY 
CHROMATOGRAPHY 
For purification, induced cells were harvested by centrifugation 
at 5000 xg for 10 min at 4°C. Cells were disrupted either by 
sonication (for volumes of 100 ml or less) or by enzymatic treatment 
(for larger volumes). For sonication, the cell pellet was suspended in 
10 volumes of Tris-Cl buffer, pH 8.0 and sonicated for 3x30 sec at 
4°C. For enzymatic treatment, 3 ml of lysis buffer (50 mM Tris-Cl, 
pH 8.0, 0.8 ml of 10 mg/ml lysozyme, 200 |LI1 of 1 mg/ml DNase I) 
were added to 1 g wet weight of E. coli cells and incubated on ice for 
30 min. After centrifuging at 15000 xg for 30 min at 4°C, the 
supernatant was retained. 
2.1.1.8 AFFINITY CHROMATOGRAPHY OF 
PROTEIN A-aMMC FUSION PROTEIN 
Three ml of IgG-sepharose 6FF (Pharmacia, Sweden) suspended 
in 50 mM K2PO4 (pH 7.2) and 1 mM MgCl� were packed in a 
�� 
Biorad Econo column (1cm x 5cm). The gel was washed with 5 bed 
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volumes of buffer A (Tris-saline-Tween 20: 50 mM Tris-Cl，pH 7.6, 
150 mM NaCl, 0.05% Tween 20), and 10 ml of buffer C (0.5 M 
acetic acid adjusted to pH 3.4 with ammonium acetate). The gel was 
washed repeatedly 2 times with buffers A and C, and finally 
equilibrated in buffer A. Cell lysate in a volume of 10-15 ml was 
applied to the column. The sample was reloaded 2 times to ensure 
complete adsorption. After sample loading, the column was washed 
with 30 ml of buffer A and 6 ml of buffer B (5 mM ammonium 
acetate, pH 5.0). Fusion protein was eluted with 5-10 ml of buffer C. 
The eluted fractions were collected in 1-ml aliquots, monitored by 
reading the absorption at 280 nm, and dialysed against distilled water 
at 4�C. 
2.1.1.9 CLEAVAGE OF PROTEIN A-aMMC FUSION PROTEIN 
BY FACTOR Xa 
For cleavage of the fusion protein, 10 |Lig of purified Protein A-
aMMC fiision protein in 10 [il of cleavage buffer (100 mM NaCl, 50 
mM Tris.Cl pH 8.0, 1 mM CaCl!，10 mM 2-mercaptoethanol) were 
mixed with 2 \il (2 |ig) of factor Xa and incubated for 6 hr at 28°C. 
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The digest was analysed by SDS-PAGE. 
2.1.1.10 SDS-PAGE ANALYSIS 
SDS-polyacrylamide gel electrophoresis was carried out in a 
12.5% gel using a Bio-Rad Mini-Protean II system (Appendix A.8). 
Electrophoresis was performed at a constant current of 50 mA (for 
dual runs) for 1 hr. The high molecular weight markers purchased 
from BRL, USA containing myosin (H-chain), phosphorylase b, 
bovine serum albumin, ovalbumin, carbonic anhydrase, 6-lactoglobin 
and lysozyme was used as a standard. The gel was stained in 
Coomassie blue solution (0.25% Coomassie blue, 30% absolute 
methanol, 10% glacial acetic acid in H2O) and destained in 
ethanol/acetic acid (8% acetic acid, 25% ethanol in H2O). 
2.1.1.11 WESTERN BLOT ANALYSIS 
The separated protein bands on SDS polyacrylamide gel were 
transferred to a nitrocellulose paper for Western blot analysis. The 
procedure is as follows: 
�� 
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A sheet of nitrocellulose paper of dimensions 4.5 cm x 9 cm 
was boiled in water in a microwave oven for 3 min to remove air 
bubbles. The treated paper was placed on 3 sheets of Whatman No.l 
filter paper prewetted with electrotransfer buffer (39 mM Glycine, 48 
mM Tris-base，0.037% SDS, 20% Methanol, pH 8.3) on a semi-dry 
electroblotter (Bio-Rad, USA). The gel with protein bands was 
removed from the gel cassette and carefully layered on top of the 
nitrocellulose paper. Another 3 sheets of prewetted Whatman paper 
were layered on top of the gel. Electroblotting was then carried out 
for 30 min at a constant current of 30 mA (0.8 mA/cm^). Afterwards, 
the nitrocellulose paper was incubated in 10 ml TBST-milk (10 mM 
Tris-Cl pH 8.0, 150 mM NaCl，0.5% Tween-20, 4% skimmed milk) 
for 1 hr to block non-specific binding sites. The paper was washed 
3x10 min with TEST, then incubated in 10 ml anti-aMMC serum 
(1:1000 diluted in TEST) at room temperature for 2 hr. The paper 
was again washed with TEST for 3x10 min, then incubated with 10 
ml goat anti-rabbit IgG alkaline phosphatase conjugate (Bio-Rad, 
1:2000 diluted in TEST) for 2 hr at room temperature. After the 
reaction, the paper was washed again with TBST for 3x10 min, and 
reacted with 10 ml of colour developing agent (freshly prepared by 
mixing 0.1 ml BCIP-Na salt (5 mg/ml in H2O), 1 ml nitroblue 
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tetrazolium (1 mg/ml in 0.15M barbital buffer, pH 9.4) and 0.02 ml 
2 M M g d � ) with gentle shaking at room temperature for 10 to 30 
min. 
2.1.1.12 ASSAY OF BIOLOGICAL ACTIVITY 
The purified protein A-aMMC fiision was assayed for 
biological activity on in vitro inhibition of protein synthesis 
according to the method of Yeung et al (1986) with modifications. 
The assay procedure is as follows: 
1. A master mix was prepared by mixing 20 |LI1 of 0.8 M creatine 
phosphate in 即，50 |il of KCl/MgCl] (2M/10mM) and 80 |LI1 
of H2O in a microfuge tube. 
2. A radioactive mix was prepared by adding 20 |LI1 of ^^ S-
methionine (Amersham SJ235, 1 mCi/66 |il/l nmole) to 40 |LI1 
of the master mix. 
3. Samples of recombinant aMMC were diluted in 0.5 mg/ml BSA. 
For each reaction, 4 |LI1 of the diluted sample and 6 |il of the 
radioactive mix were mixed. Negative control was set up using 
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0.5 mg/ml BSA instead of recombinant aMMC, positive control 
was 0.1 mg/ml native aMMC (prepared in 0.5 mg/ml BSA) 
instead of recombinant samples. 
4. To start the reaction, 30 |il of the working lysate (freshly 
prepared by 
mixing 500 |il of untreated rabbit reticulocyte lysate (Promega 
L4153)，500 |Lil sterilized H2O, 10 |LI1 of 5 mg/ml creatine 
phosphokinase, and 50 |LI1 of 1 mM hemin) were added to each 
tube. The tubes were mixed immediately and placed at 30°C for 
30 min. 
5. After reaction, a 5-|LI1 aliquot of each sample was taken and 
diluted into 1 ml of H2O. 
6. 0.5 ml of Na0H/H202 (lM/10%) was added to each sample. 
7. The samples were incubated at 37°C for 10 min. 
8. To precipitate proteins, 1 ml of ice-cold 25% TCA was added. 
The tubes were put in a 4°C refrigerator for 30 min. 
9. The precipitate was filtered through a wet Whatman GF/C filter, 
washed with 10 ml 8% TCA, and dried with 1 ml acetone. 
10. The filter was mixed with 4 ml of scintillation fluid (0.4 g 
POPOP, 4 g PPO，666 ml toluene and 334 ml Triton X-100) 
and counted in a Beckman LSI801 liquid scintillation counter. 
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2.1.2 RESULTS 
2.1.2.1 CONSTRUCTION OF pRIT2T/MMC 
The aMMC cDNA fragment cloned in a pUC18 vector was 
amplified by PCR and subsequently isolated by the procedure 
described in Section 2.1.1.2. The fragment was then subcloned into 
the plasmid pRIT2T and transformed into N4830-1 E, coli cells. The 
transformation frequency was 1x10^ colonies per |Lig DNA. Typically, 
20 |Lil of the ligation mixture would yield 5x10^ colonies. Plasmid 
DNAs from the transformants were prepared and screened by 
digestion with restriction enzymes EcoRL and BamHL A characteristic 
band of 800 bp probably representing the cDNA of aMMC could be 
found in the positive clones (Fig. 2.5). It was found that more than 
80% of the transformants carried the insert. 
The aMMC cDNA was ligated in-frame to the coding region 
of the C-terminal fragment of the IgG-binding domain of protein A. 
To facilitate the specific removal of the mature aMMC from the 
fusion protein, a short sequence (Ile-Glu-Gly-Arg) recognized by the 
blood agglutination factor Xa (Smith and Johnson, 1988) was 
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engineered between the protein A and aMMC sequence so that an 
unfused aMMC could be obtained by digesting the fusion protein 
with factor Xa. 
� 
38 
1 2 3 4 5 
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I 1 
Fig. 2.5 Digestion of pRIT2T/MMC with EcoEI and BamHl. 
Lane 1: XHindlll digest; Lanes 2 and 4: pRIT2T/MMC 
plasmid DNA from clones 1 and 2, respectively; 
Lanes 3 and 5: pRIT2T/MMC plasmid DNAs from 
clones 1 and 2 digested with EcoRI and BamHl. 
� 
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2.1.2.2 DNA SEQUENCING 
DNA sequencing was performed on pRIT2T/MMC to analyse 
the joint sequence between the protein A of the parent plasmid and 
the cloned fragment of aMMC cDNA. This procedure would also 
confirm the existence of a factor Xa site and ensure that a correct 
reading frame has been constructed in the fusion protein (Fig. 2.6). 
From the results, it is noted that the aMMC cDNA fragment 
was fused in frame to the protein A gene. The sequence of the factor 




A C G T 霸 
. : 3 m I 
GAT GTT AGC .. • (aMMC) 
g • 身 J ATT GAA GGA AGA (factor Xa) 
� G G A A T T (EcoRl) 
, GATC (Sau3l) 
e • - (protein A)…CTT AAA GAC 
Protein A Sau3I EcoRI 
5' ... CAA AGC CTT AAA GAC GAT CCG GGG AAT TCC 
Gin Ser Leu Lys Asp Asp Pro Gly Asn Ser 
Factor Xa aMMC 
ATT GAA GGA AGA GAT GTT AGC … 3' 
lie Glu Gly Arg Asp Val Ser 
Fig. 2.6 Confirmation of factor Xa cleavage site of pRIT2T/MMC 
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2.1.2.3 EXPRESSION OF PROTEIN A-aMMC FUSION cDNA 
The expression of the recombinant protein A-aMMC fusion 
was studied by Western blot (Fig. 2.7). No expression of the protein 
A gene (with or without aMMC fusion) was observed when the E. 
coli cells were grown at 30�(Lanes 4 and 6). However, when the 
temperature was changed to 40°C, an obvious band of the protein A 
expression was observed (Lanes 5 and 7-9). In lane 5，the band is due 
to the expression of the IgG-binding part of protein A. The molecular 
weight of this fragment is approximately 30000 Da. Lane 7 to Lane 
9 represent the expression of aMMC fused to this fragment. Since the 
calculated molecular weight of the aMMC fragment is 29092 Da, the 
final molecular weight of the protein A-aMMC fusion protein is 
expected to be about 60000 Da. For the protein A-aMMC fusion, a 
time-dependent expression profile was observed. It appeared that 
some degree of degradation of the fusion protein occurred during 
expression, as some minor bands of smaller sizes were observed. 
Since most protease inhibitors such as phenylmethylsulfonyl fluoride 
are also inhibitors to factor Xa, the use of these inhibitors is not 
appropriate in our system. These degraded fragments might contain 
IgG-binding domains that showed a positive signal in the Western 
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blot. Since no immunosignals were found in the parent protein A 
vector transformed cells before temperature shift, the minor bands 
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Fig. 2.7 Western blot analysis of expression of protein A-aMMC 
fusion. Lanes 1 and 10: Natural aMMC; Lane 2: E. coli 
N4830-1 at 30°C; Lane 3: N4830-1 at 40°C 3 hr; Lane 4: 
N4830-1 transformed with pRIT2T at 30�C; Lane 5: N4830-1 
with pRIT2T at 40�C 3 hr. Lane 6: N4830-1 with 
pRIT2T/MMC at 30�C; Lane 7: N4830-1 with pRIT2T/MMC 
at 40�C 1 hr; Lane 8: N4830-1 with pRIT2T/MMC at 40°C 
2 hr; Lane 9: N4830-1 with pRIT2T/MMC at 40°C 3 hr. 
� 
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2.1.2.4 PURIFICATION OF PROTEIN A-aMMC FUSION 
PROTEIN 
The protein A-aMMC fiision protein was purified on an IgG-
Sepharose affinity column according to the procedures described in 
Materials and Methods. The IgG column was loaded with the E. coli 
lysate and first washed with 30 ml buffer A (Tris-saline-Tween 20: 
50 mM Tris-Cl, pH 7.6，150 mM NaCl，0.05% Tween 20) to remove 
the unbound materials, and subsequently washed with 6 ml buffer B 
(5 mM ammonium acetate, pH 5.0) to remove the non-specifically 
bound proteins (Section 2.1.1.8). At this point the OD of the washing 
was found to be less than 0.005. The expected protein A-aMMC 
fusion was eluted with 10 ml of buffer C (0.5 M acetic acid pH 3.4) 
and the elution profile is illustrated in Fig. 2.8. The shaded fraction 
was collected and analysed by SDS-PAGE. By this method, 
approximately 2 mg of the fusion protein could be obtained from 1 
L of the E. coli culture. 
The SDS-PAGE and Western blot analysis of the protein A-
aMMC fusion protein at different stages of purification is shown in 
Figs. 2.9 and 2.10. The protein A-aMMC fusion in the soluble E. 
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coli extract was highly concentrated after a single passage through an 
IgG-sepharose column (Fig. 2.9: Lane 5 and Fig. 2.10: Lane 4). Some 
degree of impurities was detected in the purified fraction, and they 
may be due to degradation of the fusion protein co-adsorbed on the 
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Fig. 2.8 Elution profile of the protein A-aMMC fusion. 
The recombinant protein A-aMMC fusion protein was 
purifed by affinity chromatography on an IgG-Sepharose 
column. Buffer A: 50mM Tris-HCl, 150mM NaCl, 0.05% 
Tween 20 pH 7.6; buffer B: 5inM ammonium acetate 
pH 5.0; buffer C: 0.5M acetic acid pH 3.4. 
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Fig. 2.9 SDS-PAGE analysis of protein A-aMMC fusion protein. 
Lanes 1 and 6: Protein markers; Lane 2: Natural aMMC; 
Lane 3: E coli lysate, pellet fraction; Lane 4: E. coli 
lysate, soluble fraction; Lane 5: Soluble fraction after 
IgG-sepharose. 
1 2 3 4 5 
F * protein A-
i Hfite ^mmm"^^^ : _ oMMC 
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Fig. 2.10 Western blot analysis of protein A-aMMC fusion 
protein. Lanes 1 and 5: Natural aMMC; Lane 2: 
E. coli lysate, pellet fraction; Lane 3: E. coli 




2.1.2.5 CLEAVAGE OF PROTEIN A-aMMC FUSION PROTEIN 
The result of cleavage of the fusion protein by factor Xa is 
shown in Figs. 2.11 and 2.12. A considerable amount of the fusion 
protein could be cleaved by this method although there was some 
degree of incomplete digestion. This may be due to the 
conformational hindrance of the fusion protein rendering the cleavage 
site inaccessible to the enzyme. Treatment of the fusion protein with 
6 M guanidine hydrochloride followed by gradual dialysis, or by 
addition of glycerol (1-3 M) to the cleavage mixture did not enhance 
the cleavage of the aMMC moiety from the protein A (results not 
shown). 
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2.1.2.6 ASSAY OF BIOLOGICAL ACTIVITY 
The protein A-aMMC fusion protein was tested for its activity 
on in vitro inhibition of protein synthesis. Unfortunately, no 
significant activity was observed. It appeared that fusion with protein 
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Fig. 2.11 SDS-PAGE analysis of cleavage of protein A-aMMC 
by factor Xa. Lane 1: Protein markers; Lane 2: 
Natural aMMC; Lane 3: Protein A-aMMC fusion 
protein; Lane 4: Protein A-aMMC fusion protein 
after factor Xa cleavage. 
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Fig. 2.12 Western blot analysis of cleavage of protein A-aMMC 
by factor Xa. Lane 1: Natural aMMC; Lane 2: Protein 
A-aMMC fusion protein; Lane 3: Protein A-aMMC 




The aMMC cDNA was sucessfully expressed in E. coli as a 
fusion protein with protein A. The advantage of this system is that the 
protein A part of the fusion protein can serve as a purification ligand 
on an IgG-Sepharose column. This is particularly useful when the 
fusion protein is later used for unidirectional deletion (Chapter 3). In 
that case, short deleted fragments are likely to be digested by 
intracellular proteases if they are not fused to a large protein. 
Moreover, as deletion may change the chromatographic properties of 
the truncated aMMC, by having a protein A moiety attached to these 
fragments, it will facilitate their isolation by simply using an 
immobilized IgG column. In this study, the yield of the cleaved 
aMMC from the fusion protein was unsatisfactory. If this strategy 
was used, the cost of factor Xa would be prohibitive. Moreover, since 
the purified fusion protein was biologically inactive, it would appear 
that this system in expressing aMMC is unsuitable even though it 
might have advantages in enhancing purification as mentioned above. 
These findings prompted us to explore an alternative expression 
� 
system. In the following section, an unfused expression system was 
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tested. This system is essentially cost-effective and practically suitable 
for studying the general properties of the recombinant aMMC. 
Unfortunately, it lacks a convenient handle as in the case of the 
protein A fusion in isolating the final product. 
2.2 EXPRESSION OF aMMC cDNA AS AN UNFUSED PROTEIN 
2.2.1 MATERIALS AND METHODS 
2.2.1.1 CONSTRUCTION OF THE PLASMID pET/MMC 
The mature fragment of aMMC cDNA was amplified by PCR 
and cloned into the expression vector pET-8c under the control of the 
strong bacteriophage T7 promoter (Fig. 2.13). An outline of the 
construction scheme is illustrated in Fig. 2.14. Expression of this 
vector is induced by the presence of T7 RNA polymerase in the host 
cells. In order to have a tight control on expression, host cells lacking 
T7 RNA polymerase are lysogenized with the bacteriophage X DE3, 
which carries a copy of the T7 RNA polymerase gene under the 
control of the inducible laclTVS promoter. Addition of IPTG to the 
�+ 
growing culture would induce expression of T7 RNA polymerase 
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which in turn switches on the target gene carried in the plasmid pET-
8c. To further stabilize the target gene, a host strain containing a 
second plasmid pLysS is used. This plasmid would provide a small 
amount of T7 lysozyme which can serve as a natural inhibitor of T7 
RNA polymerase to reduce the basal level of the target gene 
expression, but does not prevent the induction of high levels of the 
target protein. The second advantage of the lysozyme is its ability to 
cleave a bond in the peptidoglycan layer of E. coli and allows the 
cells to lyze under mild conditions. In the expression of aMMC 
cDNA，we have used a host strain BL21 (DE3 pLysS). 
� � 
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Fig. 2.13 Plasmid Map of pET-8c 
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Primer 3 cMMC 
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Ncol aMMC BamHI 
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Fig. 2.14 Construction of pET/MMC 
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2.2.1.2 PREPARATION OF aMMC INSERT BY PCR 
The aMMC cDNA in pUC18 was amplified by PCR with 
synthetic oligonucleotide primers flanking the sequence encoding the 
mature aMMC. The primers were designed to incorporate a Ncol site 
at the 5' end and a BamHI site after the termination codon of the 
insert (Fig. 2.15). 
Primer 3: 
Ncol aMMC N-terminal 
5' CGC GCC ATG GAT GTT AGC TTT CGT TTG TCG GGT GCT GAT 3' 
Primer 4: 
BamHI aMMC C-terminal 
5' G CGC GGA TCC TTA GTA GCT AAA GCC ATG TGT TGT 3' 
Fig. 2.15 Sequences of the PCR Primers 3 and 4: 
PCR was performed in a 0.5-ml microfUge tube with the 
following PCR mix: 
lOx PCR buffer 5 inl 
dNTP mix (2 mM each) 5 i^l 
Primer 3 (0.1 i^g/jal) 1 |LI1 
Primer 4 (0.1 \igl\A) 1 
Taq DNA polymerase (5 u/|xl) 0.5 |LI1 
MMC18p8 (10 ng尔 1) 1 |il � 
Sterile dd H2O 36.5 |LII � 
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After all the components were added, the tube was vortexed 
t briefly and centrifuged to collect the contents to the bottom of the 
tube. Then 50 |LI1 of mineral oil were carefully layered on top of the 
liquid. PCR was performed in a Coy Model 60 Temperature Cycler 
with a denaturation step at 94®C for 7 min, then followed by 30 
cycles of 94�C 1 min, 50�C 2 min, 72�C 2 min, and a cycle of 94^C 
1 min, 50°C 2 min and 72°C 10 min. After PCR, the aqueous layer 
(lower layer) was transferred to another microfuge tube by using an 
autopipette tip carefully punching through the oil layer to withdraw 
the liquid, and stop just when the boundary reached the bottom. The 
PCR product was purified on a 1.5% agarose gel. The amplified band 
was excised and purified using Gene Clean (Appendix A.2). The final 
product was dissolved in 15 |LI1 of H2O or TE (pH 8.0). 
2.2.1.3 ENZYME DIGESTIONS 
Five |li1 (2 |Lig) of the PCR product from the above were mixed 
with 1 |Lil (10 u) of Ncol, 1 III (10 u) of Bamm, 2 i^l of lOx One-
Phor-All restriction buffer (Pharmacia), 1 of H2O and incubated at 
37�C for 1.5 hr. At the same time, 2 |il (1 |Lig) of plasmid pET-8c was 
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digested with the same enzymes (1 u (10 u) of Nco\, 1 |LI1 (10 u) of 
BamHI, 2 \i\ of lOx One-Phor-All buffer, 4 |il H^D) at 37°C 1.5 hr. 
After digestion, the digest was heated at 70°C for 10 min to inactivate 
the enzymes and the DNA was either gel purified or ethanol 
precipitated to remove any residues of buffer substances. Afterwards, 
the DNA was dissolved in 10 |LI1 of TE or H2O for further 
manipulation. 
2.2.1.4 LIGATION 
Ligation was carried out at for 4 hr to overnight in a 1.5-
ml microcentrifuge tube with the following mix: 
Purified insert (1 |ig) 5 |LI1 
Linearized plasmid (1 |Lig) 2 |LI1 
T4 DNA ligase (5 U/|LL1) 1 |LI1 
lOx ligation buffer 2 [il 
Sterile dd H2O 10 \il 
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2.2.1.5 TRANSFORMATION ( 
Competent cells of bacterial strain BL21(DE3, pLysS) were 
prepared as described in Section 2.1.1.4. For transformation, 20 i^l of 
the competent cells were mixed with 1 |LI1 of the ligation mix or a 
positive plasmid control (50-200 ng) and incubated on ice for 30 min 
in microfuge tubes. The tubes were then heat-shocked at 42°C for 
exactly 50 sec, and put on ice for 1 min. The transformed bacteria 
were mixed with 80 of SOC medium and incubated at 37°C for 1 
hr to express the appropriate antibiotics resistance, and streaked on an 
M9ZB agar plate containing 50 |Lig/ml amplicillin and 25 |Lig/ml 
chloramphenicol using a turn-table. 
2.2.1.6 SCREENING FOR aMMC INSERTS 
Plasmid samples after transformation were prepared as 
described in Appendix A.4. The samples were digested with Ncol and 
BamHL to confirm size of the insert. 
� 
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2.2.1.7 DNA SEQUENCING 
The DNA sequence of the cloned aMMC cDNA fragment in 
pET-8c was analysed as described in Section 2.1.1.5 and Appendix 
A.3 using the following primers (Fig. 2.16). The pET-forward primer 
is on pET-8c approximately 30 bp upstream from the aMMC cDNA 
for sequencing the first half of the fragment. The MMC-forward 
primer is near the middle of the aMMC cDNA for sequencing the 
second half • 
pET-forward primer (20 bp): 
5' AAC GGT TTC CCT CTA AAA AT 3' 
MMC-forward primer (20 bp): 
5' GGC AAG CCA AGA GAA AAA AT 3' 
Fig. 2.16 Sequencing primers for pET/MMC 
2.2.1.8 EXPRESSION OF UNFUSED aMMC cDNA 
A single colony of E. coli transformed with pET/MMC was 
inoculated into 20 ml of M9ZB containing 50 |Lig ampicillin/ml and 
25 |ig/ml chloramphenicol. The culture was shaken at 37°C ovemi^t 
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at 300-400 rpm. A 100-fold dilution of the culture was then made 
either by adding 20 |LI1 of the overnight culture into 2 ml of fresh 
M9ZB containing appropriate antibiotics for analytical purpose, or by 
adding 10 ml of the overnight culture into 1 L of fresh M9ZB with 
antibiotics for large scale preparation. The culture was shaken for 3 
hr at 37°C until the OD^ oo was 0.5 to 0.8. To induce expression, IPTG 
was added to a final concentration of 0.4 mM and the culture was 
further shaken for 2-3 hr at 37°C. Cells were harvested by 
centrifugation at 5000 xg at 4°C, and suspended in 10 volumes of 50 
mM sodium phosphate buffer, pH 7.4 containing 100 |LIM 
phenylmethylsulfonyl fluoride (PMSF). The suspension was sonicated 
for 3x30 sec on ice and centrifuged at 10000 xg for 30 min. The 
supernatant obtained in this way was used for analysis of expression. 
'-4 
2.2.1.9 SDS-PAGE ANALYSIS 
SDS-polyacrylamide gel electrophoresis was carried out in a 
12.5% gel using a Bio-Rad Mini-Protean II system as described 
before (Section 2.1.1.10). 
� 
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2.2.1.10 WESTERN BLOT ANALYSIS 
Immunoblotting the samples after SDS-PAGE was performed 
as described in Section 2.1.1.11. 
2.2.1.11 PURIFICATION OF RECOMBINANT aMMC 
Alpha-MMC in the supernatant fraction of the cell lysate was 
purified by cation exchange chromatography on a CM-Sepharose 
column of 1.5 cm diameter x 26 cm long. The column was washed 
with 50 mM sodium phosphate buffer (pH 7.4) and eluted with the 
same buffer containing 0.5 M NaCl. 
The recombinant aMMC after CM-Sepharose was further 
purified by FPLC on a Mono-S HR5/5 column (Pharmacia, Sweden). 
The column was washed with 10 mM sodium phosphate buffer (pH 
7.4) and eluted with a gradient of 0-100 mM NaCl in the same buffer. 
� 
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2.2.1.12 BIOLOGICAL ACTIVITY OF RECOMBINANT aMMC 
Alpha-MMC purified by the above procedure was assayed for 
biological activity on in vitro inhibition of protein synthesis according 
to the procedure described in Section 2.1.1.12. 
2.2.1.13 RADIOIMMUNOASSAY 
The expression level of recombinant aMMC was estimated by 
radioimmunoassay according to the procedure listed below: 
lodination of aMMC 
Preparation of iodogen tubes 
An aliquot of 50 |LI1 of iodogen solution (1 mg iodogen in 25 ml 
of dichloromethane) was added into a 1.5-ml microfUge tube. The 
tube was air-dried at room temperature overnight or heat-dried using 
a stream of hot air with a hair dryer. The iodogen-coated tubes were 
stable for 3 months when stored at -20°C. 
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lodination 
Thirty |il of purified natural aMMC (containing about 10 |Lig 
protein), 10 |LI1 of 0.15 M phosphate buffer (pH 7.4)，and 10 |LI1 Na^^ I^ 
(0.1 mCi/|Lil, Amersham) were added into an iodogen tube. The 
mixture was incubated 11 min at room temperature and afterwards 0.5 
ml of PBS was added. The mixture was transferred to a new tube and 
the reaction was allowed to quench for a further 5 min at room 
temperature. 
Separation of iodinated aMMC from unbound label 
An Ultrafree-MC filtration unit (Millipore, USA) was used to 
separate the iodinated aMMC from unbound label. The procedure 
used was according to the manufacturer's instruction. An Ultrafree-
MC filtration unit was first prewashed with 400 |LI1 of 1% BSA，1% 
sucrose solution by centrifugation for 20 min at 2000 xg in a 
microcentrifuge. Then, the iodinated aMMC mixture was added to 
the filter unit and centrifuged at 2000 xg for 20 min. The filter unit 
was then filled to the maximum with PBS and then centrifuged at 
�� 
2000 xg for 20 min. This process was repeated 3 times before the 
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iodinated aMMC was collected. The radioactivity of the iodinated 
aMMC was determined by taking 1 |LI1 of the sample mixed with 0.5 
ml of PBS and counted in a Kontron Gammamatic II Gamma counter. 
Preparation of recombinant samples for RIA 
Three ml of an overnight culture was induced to express 
aMMC expression as described in Section 2.2.1.7. Cells were 
harvested by centrifugation at 5000 xg for 5 min and suspended in 2 
ml of 50 mM phosphate buffer pH 7.4. The suspension was sonicated 
3x30 sec on ice and centrifuged at 10000 xg for 30 min at 4�C. The 
supernatant was collected and diluted 10-，100- and 1000-fold with 
RIA buffer. One hundred |LI1 of each diluted sample were used for 
radioimmunoassay. 
Radioimmunoassay 
Radioimunoassay was set up as follows: 
1. Bmax (positive control): contained 100 |LI1 ^^^I-aMMC (400 
cpm/^1), 100 |Lil anti-aMMC serum (1:4000 dilution of YOOl 
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in RIA buffer) and 100 i^l RIA buffer. RIA buffer is 0.5% 
BSA，0.1% Triton X-100，0.01% thimersol in PBS pH 7.4. 
2. Non-specific Binding (negative control): contained 100 |LI1 
aMMC (400 cpm/|Lil), 100 |LI1 normal rabbit serum (1:4000 
diluted in RIA buffer), and 100 RIA buffer. 
3. Standards/samples: contained 100 |il ^^^I-aMMC (400 cpm/|Lil), 
100 III anti-aMMC serum (1:4000 dilution of YOOl in RIA 
buffer), and 100 |LI1 standard aMMC of concentrations from 0 
to 100 ng/ml purified aMMC or recombinant samples. 
The sample mixtures were incubated at 4°C overnight. One 
hundred |LI1 of anti-rabbit IgG (1:10 diluted in RIA buffer) and 100 |LI1 
rabbit IgG (1:100 diluted of a 30 mg/ml stock in RIA buffer) were 
added and mixed. The mixtures were further incubated at 4°C 
overnight. The tubes were then centrifuged at 4000 rpm for 1 hr at 
4°C. The supematants were removed by aspiration. The tubes were 




I 2.2.2 RESULTS 
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2.2.2.1 SCREENING OF pET/MMC 
The cDNA fragment of the mature aMMC was cloned into 
pET-8c and transformed into coli strain BL21 (DE3 pLysS) host. 
For 1 |ig of the pET-8c plasmid, more than 10^ transformants were 
obtained. For 25 |il of the ligation mixture, about 10^  transformants 
were obtained. Plasmid samples from six randomly selected 
transformants were prepared and screened by digestions with Ncol 
and BamHl (Fig. 2.17). An 800-bp band corresponding to the 
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Fig. 2.17 Digestion of pET/MMC plasmid DNA with Ncol 
and BamUl. Lane 1: XHindlll digest; Lane 2-7: 
Samples of pET/MMC digested with Ncol and BamHl 
(clones 1-6, respectively); Lanes 8: pET-8c 
digested with Ncol and BamUl. 
� 
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�2.2.2.2 DNA SEQUENCING 
The DNA sequence of the aMMC cDNA cloned into the pET-
8c plasmid was analysed and compared to the published aMMC 
cDNA sequence (Ho et al" 1991). No mutations were found (results 
not shown). 
2.2.2.3 EXPRESSION OF UNFUSED aMMC cDNA 
The positive clones identified above was induced to express 
aMMC by the procedure described in Materials and Methods. The 
result of expression was analysed by SDS-PAGE (Fig. 2.18) and 
immunoblot (Fig. 2.19). In SDS-PAGE, a major band probably 
representing the recombinant aMMC protein was observed. 
Compared to the standard markers, the size of this band was found to 
be approximately 29000 Da, which is slightly larger than the natural 
aMMC standard. This is reasonable because the recombinant aMMC 
constructed in our study includes a propeptide with 10 amino acid 
residues at the C-terminal. In mature aMMC, this propeptide is 
cleaved off. It is of interest that a minor band was observed below 
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each major band, and the size of this band is equal to that of the 
natural aMMC. Since the presence of PMSF is only to able to inhibit 
serine proteases, it is not surprising that some of the recombinant 
aMMC might undergo degradation and a small quantity of the mature 
aMMC might form and was detected by Western blotting. No 
expression was observed before induction, suggesting that this system 
has a very tight control. From the SDS-PAGE result, it appears that 
the expression level of aMMC in this system was not high. However, 
this is not a disadvantage since high level expression of foreign 
proteins in E. coli always leads to the formation of denatured 
inclusion bodies, which would add difficulties to the purification of 
a biologcally active product. Before we attempted to purify the 
recombinant aMMC, the expression level of this system was 
estimated by radioimmunoassay. 
� 
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Fig. 2.18 SDS-PAGE analysis of recombinant aMMC expressed 
in E. coli. Lane 1: Protein markers; Lane 2: Natural 
aMMC; Lane 3: E. coli BL21 (DE3 pLysS); Lane 4: 
E. coli transformed with pET/MMC before induction 
of expression; Lane 5: 30 min after induction; 
Lane 6: 1 hr after induction; Lane 7: 2 hr after 
induction; Lane 8: 3 hr after induction. 
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Fig. 2.19 Western Blot analysis of recombinant aMMC expressed 
in E. coli. Lane 1: Natural aMMC; Lane 2: E. coli 
BL21 (DE3 pLysS); Lane 3: E. coli transformed with 
pET-8c before induction of expression. Lane 4: 30 min 
after induction; Lane 5: 1 hr after induction. 





The amount of recombinant aMMC expressed in the pET 
system was estimated by radioimmunoassay (RIA). A standard curve 
was obtained using natural aMMC. From the result of this analysis, 
the sensitivity of our assay was determined to be between 10 to 1000 
ng/ml (Fig. 2.20). Using this RIA, the level of expression of 
recombinant aMMC was found to be in the range of 2 to 4 |Lig/ml of 
bacterial culture, contributing to about 3% of total cellular proteins 
(Table 2.1). 
Test Bacterial Total Soluble Recombinant Expression Level 
Number Culture (ml) Proteins (/xg) aMMC (/xg) (% total soluble proteins) 
1 3 309.6 12.0 3.8 
2 3 366.0 6.0 1.6 
3 3 218.4 7.2 3.2 
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Fig. 2.20 Standard curve of radioimmunoassay of aMMG 
B: sample counts; Bo: maximum binding counts; 
NS: non-specific binding counts. Each data point 
represents the mean of triplicate. 
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2.2.2.5 PURIFICATION OF RECOMBINANT aMMC 
The soluble fraction of the cell lysate transformed with 
pET/MMC after induction was used for purification of the 
recombinant aMMC. The fraction was initially concentrated by CM-
Sepharose (Fig. 2.21) and then purified by FPLC on a Mono-S HR5/5 
column (Fig. 2.22). The purification of aMMC at different stages was 
analysed by SDS-PAGE (Fig. 2.23) and Western blotting (Fig. 2.24). 
It can be seen that the recombinant aMMC has been purified to 
homogeneity as monitored by SDS-PAGE by this procedure. From 
the blotting result, it appears that the purified protein is immuno-
reactive. Using this method, about 1 mg of purified aMMC could be 
obtained from 1 L of bacterial culture. The yield is approximately 
30%. The amount of aMMC obtained from this system was more 
than enough for our study. 
2.2.2.6 BIOLOGICAL ACTIVITY OF RECOMBINANT aMMC 
The purified aMMC was assayed for activity in in vitro 
inhibition of protein synthesis. The recombinant aMMC expressed in 
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the pET system was found to be active in the assay. The ID50 of the 
recombinant aMMC was 0.008 nM, which is less active than of that 
of naturally occurring aMMC, but is a bit more active than TCS (Fig. 
2.25). The decrease in activity of our recombinant aMMC as 
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Fig. 2.21 Purification of recombinant aMMC with CM-Sepharose. 
Buffer A: 50 mM sodium phosphate pH 7.4; buffer B: 1.5 M 
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Fig. 2.22 Purification of recombinant aMMC by FPLC. 
The recombinatnt aMMC was eluted with a NaCl gradient 
from 0 to 100 mM in 10 mM phosphate pH 7.4. 
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Fig. 2.23 SDS-PAGE analysis of recombinant aMMC. 
Lane 1: Protein markers; Lane 2: Natural aMMC; 
Lane 3: recombinant aMMC after CM-sepharose; 
Lane 4: recombinant aMMC after FPLC. 
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Fig. 2.24 Western blot analysis of recombinant aMMC. 
Lane 1: Natural aMMC; Lane 2: recombinant 
aMMC after CM-sepharose; Lane 3: recombinant 
aMMC after FPLC. 
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Fig. 2.25 Inhibition of in vitro protein synthesis by recombinant aMMC, 
natural aMMC and natural TCS. Error bars represent standard 




An unfused form of aMMC was purified from the soluble 
fraction of a E. coli lysate prepared from a host transformed with a 
T7 expression plasmid carrying the aMMC cDNA. It is known that 
there are many differences between a E. coli expression system and 
that of the eukaryotes. In E. coli, there is no cellular 
compartmentation. Foreign proteins after translation are often 
expressed in a reducing environment and are likely to form denatured 
inclusion bodies. In addition, there is also no post-translational 
modification mechanism in E. coli; hence, the recombinant aMMC 
obtained is unlikely to be glycosylated. In our study, the recombinant 
aMMC was purified from the soluble fraction of cellular proteins. 
By this procedure, the recombinant aMMC was obtained without 
solubilization and refolding, purification could be performed under 
milder conditions. The problem of low yield and protein degradation 
are of concern, however, they can be improved with the use of certain 
protease inhibitors such as PMSF. 
In our study, the recombinant aMMC was purified to 
hemogeneity as tested by SDS-PAGE. The purified aMMC was 
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found to be active in in vitro inhibition of protein synthesis. The 
decrease in activity of our recombinant aMMC is probably due to the 
presence of an extra propeptide at the C-terminal. Since the 
recombinant aMMC was produced in E. coli, it might not contain 
any carbohydrate moiety. From these results, it appears that the 
carbohydrate part of the native aMMC is not essential for the protein 
synthesis inhibiting activity. 
The level of the aMMC expression was estimated by 
radioimmunoassay. It was not high (less than 3% of total cellular 
proteins) when compared to many other over-expression systems (5-
20%). Still, a considerable amount of the recombinant protein (1-2 
mg/L culture) in the soluble fraction of the cell lysate could be 
purified from this system. This amount is more than enough for our 
analytical purposes. 
The recombinant aMMC could be recognized by an antiserum 
raised against natural aMMC as determined by both Western blotting 
and radioimmunoassay. In the following studies, this full-length 
recombinant aMMC is a good reference; particularly when genetic 
engineering techniques are used to modifiy the protein. 
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CHAPTER 3 EXPRESSION OF MODIFIED FORMS OF 
aMMC cDNA 
In the previous Chapter, the expression of a full-length aMMC 
has been studied. This full-length recombinant aMMC was found to 
be immuno-reactive. In order to fiirther investigate and determine the 
immuno-reactive regions of this molecule, different forms of aMMC 
cDNA were constructed and expressed. Since no background 
information on the immuno-reactive positions of aMMC was known, 
selected site-directed mutagenesis of the aMMC cDNA was not 
appropriate. Random mutagenesis of the whole cDNA fragment was 
not employed because it is less specific and moreover, only global 
changes in large segments of the aMMC molecule would produce a 
change in the immuno-reactivity of the recombinant aMMC. 
In our study, the aMMC cDNA was modified by unidirectional 
deletion. It was hoped that most of the structural and antigenic 
properties of aMMC could be retained in the longer fragments, 
whereas these properties would gradually be lost as these fragments 
become shorter. In our study, the full-length aMMC cDNA fragment 
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cloned in pRIT2T (Chapter 2) was subjected to unidirectional 
deletion. The protein A part of these deletion fusions might serve as 
a handle to facilitate isolation and to stabilize the shorter fragments 
so that they would not be degraded by proteolytic enyzmes. 
3.1 EXPRESSION OF DELETION FRAGMENTS of aMMC cDNA 
3.1.1 MATERIALS AND METHODS 
3.1.1.1. CONSTRUCTION OF DELETION MUTANTS 
A deletion library of aMMC cDNA was generated by the 
method of unidirectional digestion using Exonuclease III (Exo III) 
(Hoheisel and Pohl，1986). The library was constructed on the fusion 
plasmid pRIT2T. The cDNA of aMMC was fused to the protein A 
gene with a unique sequence coding for Factor Xa (Section 2.1.1.1). 
Exonuclease III degrades double-stranded DNA with blunt ends 
or recessed 3，termini. With reference to the restriction map of 
pRIT2T (Fig. 2.1), the Pstl site is a good choice as the starting point 
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for deletion. Unfortunately, this site is not unique on the plasmid. The 
aMMC cDNA fragment also contains a Pstl site. An alternative 
choice is to cleave the vector at Sail and protect the ends with a-
phosphorothioate nucleotide, then cleave at the BamHl site and start 
the deletion reactions. This method was tried but no successful 
deletion was obtained. The reason may be that the BamVH site was 
too close to the Sail site and the enzyme could not digest the DNA 
properly. 
A modified procedure described in Fig. 3.1 was found to be 
successful in generating a series of deletion mutants of protein A-
aMMC fusion using the plasmid pRIT2T. A fragment between the 
BamHl and EcoRY sites was first removed and replaced with a 
fragment containing a Nhel site from the plasmid pBR322. The 
purpose of introducing a Nhel was to increase the distance between 
this and the BamHl site. The Nhel site was cleaved and the ends were 
protected by a-phosphorothioate nucleotide. Because of the increased 
distance between the BamVH and the protected site, the BamHl site 
• could now be cleaved successfully. After this modification, 
unidirectional deletion of the plasmid could be performed starting at 
the BamHl site. 
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Fig. 3.1 Construction of deletion mutants of pRIT2T/MMC 
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3.1.1.1.1 MODIFICATION OF pRIT2T/MMC 
Two |Lig (5 |Lil) of plasmid DNA pRIT2T/MMC were mixed 
with 1 |Lil BamHI (10 u)，1 |LI1 ECOKV (10 u)，1 |LI1 lOx restriction 
buffer #3 (New England Biolabs)，5 |LI1 distilled water and incubated 
at 37�C for 2 hr. Meanwhile, 10 |LI1 (5 |Lig) of pBR322 were digested 
with the same enzymes. The large fragment from pRIT2T/MMC and 
the small fragment from pBR322 were gel purified and ligated. For 
ligation, 1 \il of the large fragment, 5 |LI1 of the small fragment, 1 \il 
lOx ligation buffer, 1 |LI1 T4 DNA ligase, and 2 |LI1 of distilled water 
were mixed and incubated at 16°C overnight. The whole ligation 
mixture was transformed into E. coli strain N4830-1 competent cells 
(Section 2.1.1.4). 
3.1.1.1.2 PREPARATION OF CLOSED CIRCULAR DNA 
Most plasmid preparations contain nicked molecules which 
have to be removed before Exo III digestion. It is known that Exo III 
could also digest from nicks and therefore randomizes the results of 
deletion. The following procedure was used to remove these nicked 
molecules: 
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Plasmid DNA of protein A-aMMC fusion from Section 
3.1.1.1.1 was prepared by standard Qiagen method (Appendix A.2) 
and dissolved in 100 [JI of distilled water (final concentration 
approximately 0.1 |Lig/|il). Then 2.5 |il of 2 M sodium acetate (pH 
4.0), 4 |Lil of 2 M NaCl and an equal volume of acid phenol 
(Appendix A.7) were added. The mixture was centrifuged at 10000 
xg for 5 min and the aqueous phase was collected. The acid phenol 
extraction was repeated one time, and 5 |il of 1 M Tris-Cl (pH 8.6) 
were added. The mixture was then extracted with 1 volume (100 |il) 
of chloroform: isoamyl alcohol (24:1) and the aqueous phase was 
retained. A 0.1 volume (10 i^l) of 2 M NaCl and 2 volumes (200 |LI1) 
of absolute ethanol were added and centrifuged at 10000 xg for 10 
min. The pellet was washed with 70% ethanol, dried briefly, and 
dissolved in TE at approximately 0.1 |ig/|Lil. 
3.1.1.1.3 ALPHA-PHOSPHOROTfflOATE NUCLEOTIDE 
(a-PdNTP) PROTECTION 
Fifty \il (5 |ig) of the above plasmid were digested with 10 u 
of Nhel for 1.5 hr at 37°C. After digestion, the enzyme was heat 
87 
inactivated at 70°C for 5 min. Then a mixture of the four a -
phosphorothioate deoxyribonucleoside triphosphates was added to a 
final concentration of 40 |LIM each. Dithiothreitol (DTT) was added 
to a final concentration of 1 mM and Klenow fragment was added to 
50 u/ml. The mixture was incubated for 10 min at 37°C. Klenow 
fragment was inactivated for 10 min at 70°C. 
The mixture was then digested with 10 u of BamHl for 1.5 hr 
at 37°C，and extracted with 1 volume of TE-saturated phenol: 
chloroform: isoamyl alcohol (25:24:1, pH 8.0). The upper layer was 
transferred to a fresh tube. Then 0.1 volume of 2 M NaCl and 2 
volume of absolute ethanol were added. The tube was incubated at -
20°C for 10 min, and centrifuged at 12000 xg for 5 min. The pellet 
was carefully washed with 70% ethanol, dried briefly and dissolved 
in 30 |Lil of TE buffer，pH 8.0. 
� 
88 
3.1.1.1.4 EXO III DIGESTION 
To 25 of linearized DNA (0.2 |ig/|iil), 12 |LI1 of 5x Exo III 
buffer (75 mM Tris-Cl, 3.3 mM MgCl?) were added. The mixture was 
incubated at 37°C for 2 min. Meanwhile, 7.5 |il-aliquots of SI 
Nuclease Mix (27 |LI1 7.4X SI buffer, 60 u SI nuclease, 172 |LI1 即） 
were added to 24 small tubes on ice. To start digestion, 200 u of Exo 
III were added, and for every 30-sec interval, a 3-|LI1 aliquot of the 
reaction mixture was withdrawn and added to the SI tubes on ice. 
The contents were mixed by pipetting up and down. After all the 
samples were taken, the tubes were moved to room temperature for 
30 min. Then 1 |LI1 of SI stop buffer (0.3 M Tris-base，0.05 M EDTA) 
was added. The tubes were heated at 7 0 � � 1 0 min to inactivate the 
SI nuclease. For gel analysis, 2 |il samples (about 40 ng of DNA) 
were removed from each time point and run on a 1% agarose gel. 
3.1.1.1.5 LIGATION 
The samples collected from each time point were mixed with 
1 |il of Klenow Mix (3 u Klenow DNA polymerase in 30 |il Klenow 
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buffer) and incubated at 37®C for 3 min. Then 1 |Lil of the dNTP mix 
(0.125 mM each of dATP, dCTP，dTTP and dGTP) was added and 
incubated for further 5 min at 37°C. The samples were then moved 
to room temperature and mixed with 40 |al of ligation mix (790 |il 
H2O, 100 [il lOx ligation buffer, 100 |LI1 50% PEG, 10 100 mM 
DTT，5 u of T4 DNA ligase). Ligation was carried out at room 
temperature for 1 hr. 
3.1.1.1.6 TRANSFORMATION 
For transformation, 10-|il aliquots of ligation products were 
added to 100 |il of N4830-1 competent cells, mixed gently, and 
incubated for 30 min on ice. The tubes were heated at 42°C for 45 
sec, on ice 2 min. Four hundred |LI1 of SOC were then added and the 
tubes were shaken at 37�C for 1 hr. The entire mixture of the 
transformation product was spread on an LB agar plate containing 50 
|ig ampicillin/ml on a turn-table. 
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3.1.1.1.7 SCREENING OF DELETION SUBCLONES 
Individual colonies were picked using sterile pipette tips and 
transferred to the bottom of individual sterile microfUge tubes. 
Remaining cells on the tips were streaked on a fresh plate for 
replication. Fifty |LI1 of 10 mM EDTA (pH 8.0) were added to each 
tube, vortex mixed. Then 50 |il of freshly prepared 2x cracking buffer 
(2 ml of 5 M NaOH, 2.5 ml of 10% SDS，10 g of sucrose, H2O to 50 
ml) were added and vortexed. The tubes were incubated at 70°C for 
5 min, and cooled down to room temperature. A 1.5-|LI1 aliquot of 4 
M KCl and 0.5 of 0.4% bromophenol blue were added and mixed. 
The tubes were placed on ice for 5 min and spinned for 3 min at 4°C. 
25-50 |il of the supematants were used to run on a 0.7% agarose gel. 
3.1.1.2 CONFIRMATION OF SEQUENCES 
The deletion clones were analysed by DNA sequencing for 




3.1.1.3 EXPRESSION OF DELETION MUTANTS 
Expression was carried out as described before (Section 
2.1.1.6). A single colony of E. coli N4830-1 transformed with a 
deletion clone was inoculated into 2 ml LB containing 50 |ig 
ampicillin/ml and shaken at 37°C overnight. The culture was diluted 
100 fold in 2 ml fresh LB containing the same antibiotics, and 
continued to shake for 3 hr or until OD6oo=0.5. To induce expression, 
the culture was transferred to a 40°C water bath and shaked for 1.5 
hr. After expression, the cells were harvested by centrifugation at 
5000 xg 5 min, and suspended in 50 |il of SDS-PAGE loading buffer. 
The suspension was sonicated 3x15 sec on ice, boiled for 5 min in a 
water bath, and centrifuged at 5000 xg for 5 min. The preparation 
was then used for SDS-PAGE (Section 2.1.1.10) and Western transfer 
analysis (Section 2.1.1.11). 
3.1.1.4 PURIFICATION OF DELETION MUTANTS 
Purification of the deletion fragments was performed following 
the same procedure for the full-length protein A-aMMC fusion 
92 
protein (Section 2.1.1.8). The eluates were collected, monitored by 
OD280 and subsequently analysed by SDS-PAGE and Western 
blotting. 
3.1.1.5 CLEAVAGE OF DELETION MUTANTS 
The truncated aMMC fragments were fused at the N-terminal 
to protein A with a factor Xa cleavage site in between. Since 
purification of the deletion mutants was not satisfactory, the crude E. 
coli lysate after expression of the aMMC cDNA fusion was used for 
cleavage. E. coli cells were prepared and induced for expression as 
described before (Section 2.1.1.6). Twenty |LI1 of the cell extract in 
cleavage buffer (100 mM NaCl, 50 mM Tris.Cl pH 8.0, 1 mM CaCl】， 
10 mM 2-mercaptoethanol) were mixed with 1 |LI1 (1 |iig) of factor Xa 
and incubated for 6 hr at 28°C. The digest was analysed by SDS-
PAGE. 
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3.1.1.6 SUBCLONING OF THE aMMC cDNA FRAGMENTS 
Four clones respresenting different lengths of aMMC fragments 
were selected from the deletion library and subcloned into the 
plasmid pET-8c for unfused expression. For subcloning，two PCR 
primers (Fig. 3.2) were used to amplify the deletion fragments on 
pRIT2T. Primer 5 carries an Nco\ site and a common sequence 
encoding the N-terminal of aMMC and primer 6 has a BamHl site at 
the 5，end and shares a common sequence on the vector pRIT2T just 
after the deletion fragment. An outline of this cloning procedure is 
illustrated in Fig. 3.3. 
aMMC Fusion Primer 5: 
Ncol aMMC 
5' TTTT CCATGG GAT GTT AGC TTT CGT TTG 3' 
aMMC Fusion Primer 6： 
BaihHI common 3 ' end sequence of truncated ofMMC 
5, GGG GGATCC TAG TTA TTT ATC GTC CAT TCC GAC 3, 
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Fig. 3.3 Subcloning of aMMC deletion fragments into pET-8c 
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PCR was performed as described before (Secion 2.1.1.2). 
Transformation and screening were carried out as in Section 2.2.1.5. 
3.1.1.7 EXPRESSION OF THE UNFUSED DELETION 
FRAGMENTS 
Expression of the unfused deletion fragments of aMMC in the 
pET system was studied as described before (Section 2.2.1.7). 
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3.1.2 RESULTS 
3.1.2.1 DESIGNATION OF THE DELETION MUTANTS 
Unidirectional deletions were carried out at different time points 
of incubation with Exo III. For identification, groups of deletion 
clones obtained for each time point were designated by a letter. 
Individual clones from each mutant group were identified by the 
group letter followed by a number. The numbers of transformants 
obtained in each mutant group are listed in Table 3.1: 
Mutant Time-point No. of Mutant Time-point No. of 
group (min) transformants group (min) transformants 
A 0.5 24 K 5.5 1 
B 1 3 L 6 3 
C 1.5 5 M 6.5 10 
D 2 19 N 7 5 
E 2.5 1 O 7.5 6 
F 3 13 P 8 4 
G 3.5 5 Q 8.5 6 
H 4 13 R 9 4 
I 4.5 8 S 9.5 1 
J 5 4 T 10 3 
Table 3.1 Designation of deletion mutants 
97 
3.1.2.2 SCREENING OF DELETION MUTANTS 
The plasmid DNAs isolated from randomly selected clones 
were analysed (Fig. 3.4). A gradual decrease in the plasmid size in 
response to different time of digestion was observed. The size range 
of the plasmids was found to be between 4000 to 5000 bp. The 
purpose of this preliminary screening was to monitor the validity of 
the deletion, precise information on the individual plasmids would be 
analysed by DNA sequencing. 
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Fig. 3.4 Analysis of plasmid size of deletion mutants. 
Plasmid DNAs from mutant groups of different time 
points were prepared by mini-prep and run on 0.8% 
agarose gel. Lanes 1 and 15: XHindlll digest; Lane 2: 
Mutant Al; Lane 3: Mutant B2; Lane 4: Mutant Dl; 
Lane 5: Mutant D3; Lane 6: Mutant F2; Lane 7: Mutant 
Gl; Lane 8: Mutant HI; Lane 9: Mutant 12; Lane 10: 
Mutant K2; Lane 11: Mutant Ml; Lane 12: Mutant 01. 
Lane 13: Mutant SI; Lane 14: Mutant Tl. 
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3.1.2.3 DNA SEQUENCING 
The precise length and sequence of the aMMC deletion 
fragments were analysed by DNA sequencing. DNA sequencing was 
performed using a reverse primer approximately 30 bp downstream 
from the deletion site on the plasmid pRIT2T (Fig. 3.5). Among the 
deletion mutants (Table 3.1), six clones (Al, Dl, F2, HI, Ml, Ol) 
were selected for characterization by DNA sequencing (Figs. 3.6, 3.7, 
3.8, 3.9，3.10 and 3.11). These clones were selected because they 
gave better transformation efficiency. The higher number of 
transformants means an increased chance of obtaining a correct 
construct. A summary of the sequencing results is illustrated in Fig. 
3.12. It is noted that for deletion mutant，O’，the aMMC cDNA 
fragment has been completely deleted. This implies that the deletion 
clones beyond this time point are no longer suitable for fragment 
studies. From the results, a termination signal could be found after 
the coding sequnece in clone Dl, F2, HI and Ml. For Al, no 
termination signal was found in between the 3，end common 
sequence and the deletion fragment. It is expected that expression of 
this clone would terminate somewhere after the common 3，end 
� 
sequence as a termination signal would be provided by the pRIT2T 
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vector at this point. 
common 3‘ end sequence 
protein A truncated aMMC cDNA -30 bp EcoRl 
5' ‘ ‘ ‘ 3, 
< 
Direction of sequencing pRIT reverse primer 
Fig. 3.5 Sequencing strategy of aMMC deletion mutants 
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aMMC cDNA 1-747 pRIT2T 
5' GCA GAA GGT / GCA GCA 3' 
Ala Glu Gly Ala Ala 
Fig. 3.6 DNA sequencing analysis of deletion mutant Al 
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aMMC cDNA 1-627 pRIT2T 
5' GGA ATA TTT / AGC AGC 3' 
Gly lie Phe Ser Ser 
Fig. 3.7 DNA sequencing analysis of deletion mutant D1 
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OfMMC cDNA 1-573 pRIT2T 
5' GAA AAC AGT / TGC AGC 3' 
Glu Asn Ser Cys Ser 
Fig. 3.8 DNA sequencing analysis of deletion mutant F2 
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aMMC cDNA 1-537 pRIT2T — 
5' AGA GAC GCG / GAG TGA 3' 
Arg Asp Ala Glu *** 
Fig. 3.9 DNA sequencing analysis of deletion mutant HI 
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aMMC cDNA 1-423 pRIT2T — > 
5' TTG CTG CAT / TAG CAG 3' 
Leu Leu His *** Gin 
Fig. 3.10 DNA sequencing analysis of deletion mutant Ml 
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Fig. 3.11 DNA sequencing analysis of deletion mutant 01 
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I MMC CDNA 1-789 1 
Protein A Xa TCG AGC TAG TAG GGA 168 bp common 3' end sequence 
Intact I I I ， *************** 
aMMC Ser Ser Tyr *** 
263 
I MMC cDNA 1-747 , 
Protein A Xa GAA GGT GCA GCA CGC 9 bp common 3' end sequence 
Clone Al | | [ *************** 
Glu Gly Ala Ala Arg 
249 
I MMC CDNA 1-627 ~ , 
Protein A Xa ATA TTT AGC AGC ACG CCA TAG 17 bp common 3' end sequence 
Clone D1 I I I *************** 
lie Phe Ser Ser Thr Pro *** 
209 
� M M C cDNA 1-573 ~ | 
Protein A Xa AAC AGT TGC AGC ACG CCA TAG 17 bp common 3' end sequence 
Clone F2 | | I *************** 
Asn Ser Cys Ser Thr Pro *** 
191 
� M M C cDNA 1-537 —| 
Protein A Xa GAC GAG GAG TGA C common 3' end sequence 
Clone HI | | 丨 *************** 
Asp Glu Glu *** 
179 
|— MMC cDNA 1-423-1 
Protein A Xa CTG CAT TAG 17 bp common 3' end sequence 
Clone Ml I I I **************** Leu His *** 
141 
Protein A n pRlT2T 
GTG AAG CTC GCA GCA 25 bp common 3‘ end sequence 
Clone 01 I **************** 
Common 3‘ end sequence： 
5' TGG CGA TGC TGT CGG AAT GGA CGA TGT CCC 3' 
Fig. 3.12 Summary of sequences of deletion clones. 
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3.1.2.4 EXPRESSION OF DELETION MUTANTS 
The expression of the truncated aMMC fusion proteins was 
monitored by Western blotting and the results are illustrated in Fig. 
3.13. It was found that the aMMC fragment was completely deleted 
in clone Ol. The positive signal observed for this clone (Lane 1) 
might be due to the expression of protein A, since protein A would 
interact with the second antibody in the assay and give a positive 
signal. For expression of the deletion fusions, a decrease in the major 
band size was found to correlate with the time of digestion. The 
minor bands might be due to the binding of the antibodies to the 
fusion proteins degraded to various degrees. 
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Fig. 3.13 Western blot analysis of expression of protein A-aMMC 
deletion fragment. Lane 1: Deletion clone 01; Lane 2: 
Deletion clone Ml; Lane 3: Deletion clone HI; Lane 4: 
Deletion clone F2; Lane 5: Deletion clone Dl; Lane 6: 
Deletion clone Al; Lane 7: Full-length protein A-aMMC 
fusion protein 
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3.1.2.5 PURIFICATION OF THE FUSION FRAGMENTS 
Attempts were made to purify the protein A-deletion fusions 
using the same procedure as the full-length fusion protein (Fig. 3.14). 
Following elution, only proteins extracted from clone Al showed an 
obvious absorption peak as monitored by OD28o- The fractions 
corresponding to the position of this peak for all the deletion clones 
were collected and analysed by SDS-PAGE (Fig. 3.15) and Western 
blotting (Fig. 3.16). Except for clones Al, all the other fusion 
proteins derived from these deletion clones could not be purified. It 
appeared that the IgG-binding properties of the protein A was 
somehow affected by deletion of aMMC sequence fused to it. The 
reason why a shortened fragment of aMMC would have such a 
detrimental effect on the affinity of the protein A domain for IgG is 
not clear. 
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Fig. 3.14 Elution of protein A-fusions of aMMC deletion fragments. 
Soluble fractions of cell ly sates from clones Al, Dl, F2, HI and Ml 
after induction of expression were purified by IgG-Sepharose affinity 
chromatography. Contents between fraction 3 and fraction 6 were 
collected and pooled for analysis. Buffer C: 0.5M acetic acid pH 3.4. 
1 2 3 4 5 
Fig. 3.15 SDS-PAGE analysis of the eluates from Fig. 3.14. 
Lane 1: clone Ml; Lane 2: clone HI; Lane 3: clone F2; 
Lane 4: clone Dl; Lane 5: clone Al. 
Fig. 3.16 Western blot analysis of the eluates from Fig. 3.14. 
Lane 1: clone Ml; Lane 2: clone HI; Lane 3: clone F2; 
Lane 4: clone Dl; Lane 5: clone Al. 
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3.1.2.6 DIGESTION OF DELETION MUTANTS BY FACTOR Xa 
The results of digestion of the deletion fusions in the crude E. 
coli lysates are shown in Fig. 3.17. All of the fusion proteins elicit a 
different degree of digestion. Since protein A would interact with the 
second antibody in the Western blot, the protein A band was visible 
in all the digested samples (molecular weight approximately 30000 
Da). On the other hand, the aMMC fragment released after digestion 
may not be immuno-reactive because the epitope carrying fragment 
might have been deleted. From the results presented in Fig. 3.17, a 
band corresponding to the aMMC deletion fragment could be 
observed in clones Al, D1 and F2. Whether there was an immuno-
reactive fragment released in clone HI and Ml is not certain. In 
order to further confirm and clarify these findings, we subcloned the 
fragments of the truncated aMMC into pET-8c and examined the 
unfiised proteins produced in this manner. 
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Fig. 3.17 Western blot analysis of digestion of protein A-aMMC 
deletion fusions by Factor Xa. Lane 1: Full-length 
protein A-aMMC fusion protein; Lane 2: Full-length 
protein A-aMMC fusion protein digested with factor Xa; 
Lane 3: Deletion Mutant Al; Lane 4: Al digested with 
factor Xa; Lane 5: Dl; Lane 6: D1 digested with 
factor Xa; Lane 7: F2; Lane 8: F2 digested with factor 
Xa; Lane 9: HI; Lane 10: HI digested with factor Xa; 
Lane 11: Ml; Lane 12: Ml digested with factor Xa. 
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3.1.2.7 SUBCLONING OF aMMC DELETION FRAGMENTS 
INTO pET-8c 
Four deleted aMMC cDNA fragments from pRIT2T (Clones 
Dl, F2, HI and Ml) were amplified by PCR and subcloned into pET-
8c for unfused expression. The clone Al was not selected because 
there was no termination signal found after the coding sequence and 
the size of this fragment was close to full-length. The purpose of this 
subcloning is to further confirm the immuno-reactive properties of 
these fragments. Plasmid DNA samples from positive transformants 
were prepared by the method of Magic Prep (Promega, USA) and 
digested with Ncol and BamHl to confirm the existence of the 
deletion inserts (Fig. 3.18). 
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一 2027 
Fig. 3.18 Digestion of plasmid DNAs from unfused aMMC deletion 
mutants with Ncol and BamRl. Lane 1: Unfused 
deletion D1 before digestion; Lane 2: Unfused 
deletion Ml digested with Ncol and BamYil\ Lane 3: 
Unfused deletion HI digested with Ncol and BamYil', 
Lane 4: Unfused deletion F2 digested with Ncol 
and Barnm-, Lane 5: Unfused deletion D1 digested 
with Ncol and Lane 6: pET/MMC (full-length) 
digested with Ncol and BamRV, Lane 7: 123-bp DNA 
markers; Lane 8: XHindlll digest. 
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3.1.2.8 EXPRESSION OF THE UNFUSED aMMC DELETION 
FRAGMENTS 
The result in the expression of deletion clones Dl，F2，HI, Ml 
is shown in Fig. 3.19. All the deleted aMMC fragments were found 
to be immuno-reactive when screened with the anti-aMMC serum 
RB004. The lower band in lane 3 was found to be a non-specific 
interference signal probably arising from electrophoresis by repeated 
experiments. The shortest fragment with positive immuno-reactivity 
was found in，M，which has about one-half of the aMMC amino acid 
sequence deleted from the C-terminal (i.e., from aa263 to 142). 
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Fig. 3.19 Western blot analysis of unfused aMMC deletion mutants. 
Lane 1: Full-length recombinant aMMC; Lane 2: Unfused 
deletion Dl; Lane 3: Unfused deletion F2; Lane 4: Unfused 




Following the expression of the full-length aMMC cDNA, the 
immuno-reactivity of truncated aMMC fragments was studied by 
Exonuclease III digestion and Western blotting. A set of aMMC 
fragments of different lengths with deletion from the C-terminal were 
produced as a fusion protein with a protein A expression vector. The 
sequences of the deletion fragments were determined by DNA 
sequencing. The advantage of this system is that a series of truncated 
aMMC could be obtained. The longer fragments would presumably 
retain much of the intact properties and as the fragment size becomes 
shorter and shorter, these properties would gradually be lost. 
To determine the epitopic regions of the aMMC molecule, it 
is important to find out which deleted fragments is responsible for 
immuno-reactivity. The fusion proteins have to be cleaved to release 
the truncated aMMC fragments before they can be studied because 
the protein A domain would cross-react with the second antibody and 
interfere with the results. In our study, the protein A moiety of the 
fusion proteins was cleaved off by factor Xa. All of the fusion 
proteins were cleavable to different degree. It appears that all of the 
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factor Xa-releasable fragments were immunogenic. This was fiirther 
confirmed by the expression of the deletion fragments as unfused 
proteins. The smallest fragment ’M，in this series contained only 
amino acid sequence 1-141. This suggests at least one or more 
epitopic regions are present in this sequence. However, the possibility 
that there are other epitopic determinants present in the deleted part 
of the aMMC polypeptide can not be ruled out. 
In the following section, molecular fragmentation was studied 
by a different approach. A chimeric protein of aMMC and TCS was 
made. In this protein, only the central region of the polypeptide is 
from aMMC, while the two ends are from TCS. We hope using this 
hybrid protein, the similar and distinctive epitopic regions of these 
molecules can be fiirther resolved. 
� 
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3.2 EXPRESSION OF A CHIMERIC aMMC/TCS cDNA 
Alpha-MMC and TCS are highly homologous in their amino 
acid sequence. They also have similar biological activity and 3-
dimensional structures. It is of interest to construct a chimeric 
molecule from these two proteins and study the properties of the 
chimeric molecule. In order to retain as much of the sequential 
similarities in the chimeric protein, the strategy of sequence swapping 
was used. In this construct, the central segment of TCS is replaced 
by the corresponding segment from aMMC. The TCS cDNA was 
chosen as the leading sequence because of its high expression level 
in the pET system. Alpha-MMC was placed in the middle of the 
hybrid molecule because the immuno-reactive property of this region 
was not revealed in our previous studies. By sequence swapping, the 
properties of the fragments can be studied on an intact molecule 
rather than truncated fragments. It is hoped that the chimeric protein 
would retain much of the biological and conformational properties 
which are useful in studying the structure-function relationship of 
these two proteins. 
� 
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3.2.1 MATERIALS AND METHODS 
3.2.1.1 CONSTRUCTION OF THE MMC/TCS CHIMERIC 
PLASMID (pET/MMC-TCS) 
The strategy in the construction of pET/MMC-TCS is described 
in Figs. 3.20 and 3.21. Our aim was to remove the middle region of 
the TCS cDNA between the Pstl and Seal sites and replace it with a 
corresponding aMMC cDNA fragment. Unfortunately, the Pstl site 
is not unique on pET58210 (a TCS cDNA cloned in pET-8c). To 
facilitate digestion, the intact TCS cDNA fragment was first 
subcloned into a carrier plasmid derived from pACYC177. With this 
plasmid, a fragment between the Pstl site and Seal site on the TCS 
cDNA could be removed and substituted by the middle fragment of 
aMMC cDNA. Moreover, this chimeric cDNA was digested by Ncol 




/ / \scal 
/ pfG104 \ / Y 
(pUC18 based) 1 ( pACYC177 j 对工 
Kn^  
digested with £coRI 
> � 
digested with Ban\ 
i . 
EcoRl Ban\ Hindi Ncol Banl EcoRI 
I I I I I I z \ 
1 1100 广 
— Q 
\ Banl 
digested with Banl ^ 
Banl 
Y 
Banl Hindi Ncol Banl / 
—212 — 193 \ / Dephosphorylation 
405 bp fragment \ 
/ Ligation BamRl 
Hindi Seal. p,a / 广 
f V . f 1 
/ Carrier Plasmid \ . , ” … … \ / 
I (pACYC177based)J 編 digested w i t h - I / — H I \ 六 I 
j^Ncol ^ ^ 乂 
Banl 
Fig. 3.20 Construction of a carrier plasmid for cloning of MMC/TCS chimeric cDNA 
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Fig. 3.21 Construction of chimeric plasmid pET/MMC-TCS 
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3.2.1.1.1 DIGESTION OF pfG104 - PREPARATION OF GHllOO 
FRAGMENT 
Ten |Lil of pfG104 (1.5 |Lig/|Lil) were mixed with 4 |LI1 lOx OPA+ 
buffer (Pharmacia, Sweden), 1 |il of EcdSl (10 u) and 5 |LI1 of sterile 
water in a microfuge tube. The mixture was incubated at 37°C for 3 
hr. The 1100-bp fragment (GHllOO) was gel purified and dissolved 
in 10 |Lil of TE buffer (pH 8.0). 
3.2.1.1.2 PREPARATION OF GH405 FRAGMENT 
Ten |Lil of the above insert preparation (2 |Lig/10 |il) were mixed 
with 1 i^l of lOx OPA+ buffer, 2 |LI1 of Banl (10 u), 7 |LI1 of distilled 
water, and incubated at 37°C for 1.5 hr. The 405-bp fragment 
(GH405) was gel purified and dissolved in 10 of TE buffer (pH 
8.0). 
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3.2.1.1.3 DIGESTION OF pACYC177 
Eight III of pACYC177 (1.5 |Lig/|Lil) were mixed with 1 |LI1 of 
lOx OPA+ buffer, 8 [il of Banl (10 u)，9 of distilled water, and 
incubated at 37�C for 1.5 hr. The large fragment (pACYC 177-2727, 
2727 bp) was gel purified and dissolved in 10 |LI1 of TE buffer (pH 
8.0). 
3.2.1.1.4 DEPHOSPHORYLATION, LIGATION AND 
TRANSFORMATION 
A 15.5-|LI1 aliquot of pACYC 177-2727 were mixed with 2 |LI1 of 
lOx CIP buffer, 2.5 (0.25 u) CIP and incubated at 37°C for 30 
min. After incubation, the tube was placed in an 85�C water bath for 
10 min to inactivate the enzyme. The dephosphorylated fragment was 
purified by Gene Clean (Appendix A.2) and dissolved in 5 |LI1 of 
water. For ligation, 2 |LI1 of the fragment were mixed with 1 [il of lOx 
ligation buffer, 1 |LI1 ofT4 DNA ligase and 6 |LI1 of water. The ligation 
mix was incubated at 16°C overnight. For transformation, 5 |LI1 of the 
� 
ligation mix were diluted with 5 i^l of TE buffer (pH 8.0)，and added 
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to 100 |Lil of JM109 competent cells (from -70°C stock and thawed on 
ice). The mixture was incubated on ice for 30 min, heat-shocked at 
42°C for exactly 2 min, and placed on ice for 1 min. Four hundred 
|il of SOC were then added and the mixture was incubated at 37°C 
for 40 min. 100 [d of the transformation mixture were used to spread 
on an LB agar plate containing 50 |ig/ml kanamycin. The plate was 
incubated in an inverted position at 37°C overnight. 
3.2.1.1.5 CONFIRMATION OF INSERT ORIENTATION 
Plasmid DNAs from the transformants were prepared by 
standard technique (Appendix A.4) and digested by Ncol and Pstl to 
confirm correction orientation of the insert ligation. 
For digestion, 5 |LI1 of the plasmid DNA were mixed with 2 |LI1 
lOx OPA+ buffer, 1 |LI1 of Pstl (10 u), 12 \il water. The mixture was 
incubated at 37°C for 1 hr. Then another 3 |al of lOx OPA+ buffer 
were added, mixed with 1 |il of Ncol and 1 |LI1 water, and incubated 
at 37°C for 1 hr. 5 |LI1 of the digest were used to run on a 1% agarose 
gel. Clones with a 423-bp insert fragment were selected for fiirther 
cloning procedures. 
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3.2.1.1.6 PREPARATION OF A FRAGMENT WITHOUT Pstl, Seal 
AND Hindi SITES 
Five |il (5 |Lig) of the plasmid DNA prepared from Section 
3.2.1.1.4 was mixed with 1 |il of Ncol, 1 |il of BamHI, 2 |LI1 of lOx 
OPA+ buffer, 1 |LI1 of water. The mixture was incubated at 37°C for 
2 hr. The digest was analysed on a 0.8% agarose gel and two 
fragments with sizes of 1405 bp and 2935 bp were obtained. The 
1405-bp fragment band was cut and purified with Gene Clean 
(Appendix A.2). 
3.2.1.1.7 PREPARATION OF THE 750-bp TCS FRAGMENT 
The 750-bp TCS fragment was prepared by cutting the TCS-
containing plasmid TCS58210 with Ncol and BamHI. For digestion, 
5 |Lil (2 |Lig) of TCS58210 were mixed with 1 |LI1 of BamHI, 1 |LI1 of 
Ncol, 2 i^l of lOx OPA+ buffer, 1 |LI1 of water, and incubated at 37°C 
for 2 hr. The 750-bp fragment was spearated on 1% agarose gel and 
purified with Gene Clean (Appendix A.2). 
� 
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3.2.1.1.8 LIGATION OF THE TCS FRAGMENT 
(PREPARATION OF pACYC177/TCS) 
The 750-bp TCS fragment was ligated to the large fragment 
prepared from Section 3.2.1.1.6. For ligation, 3 |LI1 (1 |ig) of the 1405-
bp fragment (Section 3.2.1.1.6) were mixed with 2 |LI1 (1 |Lig) of the 
TCS 750-bp fragment, 1 |il lOx ligation buffer, 1 |LI1 T 4 DNA ligase, 
3 |Lil water, and incubated at 16°C overnight. After ligation, the total 
volume of the ligation mix was used to transform 100 |LI1 of JM109 
competent cells as described before (Section 3.2.1.1.4). The 
transformants were plated on a 1% agar plate containing 50 |Lig/ml 
kanamycin and incubated inverted overnight at 37°C. Positive clones 
were confirmed by standard preparation of the plasmid DNA 
(appendix A.4) followed by digestion with BamHl and Ncol. 
3.2.1.1.9 CLEAVAGE OF pACYC177/TCS WITH Seal AND Pstl 
Ten |il (4 |ig) of pACYC177/TCS prepared from Section 
3.2.1.1.8 were mixed with 1.5 |LI1 lOx OPA+ buffer, 1 |LI1 of Pstl, 3 |LI1 
of water (total 15.5 |LI1), and incubated at 37�C for 2.5 hr. After 
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incubation, the mixture was heat-inactivated in an 85°C water bath 
for 30 min. Then 0.5 |LI1 of lOx OPA+ buffer, 2 |il of Seal (6 U/|LI1) 
and 2 |il of water were added. The mixture was briefly stirred with 
the pipette tip and incubated at 37°C for 2.5 hr. The digest was then 
separated on a 1% agarose gel and the large fragment was purified 
with Gene Clean (Appendix A.2). 
3.2.1.1.10 PREPARATION OF THE P^rt/^al-DIGESTED aMMC 
cDNA FRAGMENT 
Three i^l (1.5 i^g) of MMC18p8 (pUC18 with an aMMC cDNA 
insert) were mixed with 1 |al of lOx OPA+ buffer, 1 of Pstl, 5 |LI1 
of distilled water. The mixture was incubated at 37°C for 2 hr, and 
heat-inactivated at 85°C for 20 min. Then 3 |LI1 of lOx OPA+ buffer, 
1 of Seal, 6 of distilled water were added. The mixture was 
further incubated for 2 hr at 37°C, The digest was analysed on a 1.2% 
agarose gel and the 252-bp fragment was purified by Gene Clean 
(Appendix A.2). 
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3.2.1.1.11 LIGATION OF THE 252-bp FRAGMENT 
Three |LI1 (1 |Lig) of the 252-bp fragment from Section 3.2.1.1.10 
were mixed with 2 |il (0.5 |ig) of the large fragment prepared from 
Section 3.2.1.1.9, 1 |il of lOx OPA+ buffer, 0.5 |LI1 of T 4 DNA ligase, 
3.5 |Lil of distilled water, and incubated at 16°C overnight. The whole 
ligation mixture was used to transform 100 |LI1 of JM109 competent 
cells as described before (Section 3.2.1.1.4). The transformants were 
plated on an LB agar plate containing 50 i^g/ml kanamycin. Positive 
clones were confirmed by standard preparation of the plasmid DNA 
(Appendix A.4) and digestion with BamHL and Ncol. At this stage, 
the plasmid contained an insert of the MMC/TCS chimeric fragment 
cloned at Ncol/BamHl sites. 
3.2.1.1.12 CLONING OF MMC/TCS CHIMERIC FRAGMENT 
INTO pET-8c 
An MMC/TCS chimeric fragment was prepared from the 
� 
plasmid described in Section 3.2.1.1.11 by digestions with Ncol and 
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BamHi. For digestion, 5 |il (2 |Lig) of the plasmid were mixed with 1 
|Lil Ncol 1 |Lil of Barnm, 2 of lOx OPA+ buffer, 1 |LI1 of distilled 
water, and incubated at 37°C for 2 hr. Meanwhile, the plasmid pET-
8c was digested with the same enzymes. The digested fragments were 
separated on a 1% agarose gel and purified by Gene Clean (Appendix 
A.2). For ligation, 3 |LI1 (1 |Lig) of the MMC/TCS chimeric fragment 
were mixed with 5 |LI1 (2 |ag) of the linearized pET-8c, 1 |LI1 of lOx 
ligation buffer, 1 of T4 DNA ligase, 3 |LI1 of distilled water, and 
incubated at 16°C overnight. The whole ligation mixture was used to 
transform 100 |LI1 of BL21(DE3/pLysS) competent cells as described 
before (Secion 4.1.1.4). The transformants were plated on an M9ZB 
plate containing 50 |ig ampicillin/ml and 25 |Lig chloramphenicol/ml. 
Positive clones were confirmed by standard preparation of the 
plasmid DNA followed by Ncol/BamUl digestions. 
3.2.1.2 EXPRESSION OF THE pET/MMC-TCS 
A single colony of bacterial strain BL21(DE3 pLysS) 
transformed with pET/MMC-TCS was inoculated into 2 ml of M9ZB 
containing 50 |Lig ampicillin/ml and 25 |Lig chloramphenicol/ml. The 
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culture was shaken at 37°C overnight at 300-400 rpm. Then 20 |LI1 of 
the culture were added to 2 ml of fresh M9ZB containing appropriate 
antibiotics. The culture was shaken for 3 hr at 37°C. To induce 
expression, IPTG was added to a final concentration of 0.4 mM and 
the culture allowed to grow for 2-3 hr at 37°C. After expression, the 
cells were harvested by centrifugation at 5000 xg at 4°C, and 
suspended in 100 |LI1 of SDS-PAGE loading buffer. The suspension 
was then sonicated for 3x30 sec on ice, incubated in a boiling water 
bath for 5 min, and centrifuged at 10000 xg for 30 min. The 
supernatant was used for SDS-PAGE and Western Blot analysis. 
3.2.1.3 SDS-PAGE ANALYSIS 
SDS-polyacrylamide gel electrophoresis was performed on 
12.5% gel using the Bio-Rad Mini-Protean II system as described in 
Section 2.1.1.10. 
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3.2.1.4 WESTERN BLOT ANALYSIS 
Western blot of the protein samples after SDS-PAGE was 
performed as described in Section 2.1.1.11. The expression of MMC-
TCS chimeric protein was monitored using two batches of anti-
aMMC sera RB004 and RB006 and a batch of anti-TCS serum 
87047. 
3.2.1.5 PURIFICATION OF MMC-TCS CHIMERIC PROTEIN 
Purification of the MMC-TCS chimeric protein was carried out 
following the same procedure as described in Section 2.2.2.5 by ion-
exchange chromatography with CM-Sepharose. Eluate was monitored 




3.2.2.1 CONSTRUCTION OF pET/MMC-TCS 
An outline of the cloning procedure is illustrated in Figs. 3.20 
and 3.21. A TCS cDNA fragment (approx. 750 bp) was isolated 
from the plasmid pET58210 by digestion with Ncol and BamHI and 
ligated to the carried plasmid derived from pACYC177 (Fig. 3.22). 
Another fragment representing the inner region of aMMC cDNA 
(cDNA positions 355-606, 252 bp) was obtained by digestion of the 
plasmid MMC18p8 with Pstl and ffhal (Fig. 3.23). This fragment 
was then ligated to the carrier plasmid carrying the TCS fragment 
pre-digested with Pstl and Seal, To monitor the cloning process, 
randomly selected transformants of this construct were digested with 
Ncol and BamHI (Fig. 3.24). It can be seen that a characteristic band 
of 750 bp, probably representing the size of the chimeric insert, was 
found in the selected transformants. This chimeric fragment was then 
removed from the carrier plasmid by Ncol and BamHI digestions and 
cloned into pET-8c for expression. To characterize pET/MMC-TCS, 
selected transformants were digested with various restriction enzymes 
� 
to confirm the sequence alignment of the construct. The digestion 
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pattern of pET/MMC-TCS from a clone hybrid-15 is illustrated in 
Fig. 3.25. Lane 5 is the XHindlll DNA marker, lane 4 is the hybrid-
15 plasmid before digestions. In lane 3, hybrid-15 was digested with 
Ncol and BamHL Three fragments were observed: the characteristic 
750 bp band probably representing the size of the chimeric insert, the 
3614 bp band representing digested plasmid and the 5391 band due 
to incomplete digestion. In lane 2，hybrid-15 was digested with Pstl 
and Seal and yielded two bands. Since the Seal site in the insert was 
lost during ligation, the 1400 bp band is due to the distance between 
the Pstl and a Seal site present on pET-8c. In lane 1，hybrid-15 was 
digested with Pstl and Hhal. As there are 31 Hhal sites present in the 
plasmid, a smear was observed in this digestion. 
� 
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Fig. 3.22 The purified TCS insert used for construction of 
pET/MMC-TCS. Lane 1: 123-bp DNA markers; Lane 2: 
Ligation of the TCS cDNA and pACYC177; Lane 3: 







Fig. 3.23 The 252-bp fragment between Pstl and Hhal sites in 
aMMC for the construction of pET/MMC-TCS. 
Lane 1: 123-bp DNA markers; Lane 2: MMC cDNA digested 
with Pst\\ Lane 3: MMC cDNA digested with Pstl and 





Fig. 3.24 Confirmation of the 750-bp fragment of MMC-TCS chimeric 
cDNA in the carrier plasmid derived from pACYC177 
(pACYC/hybrid). Lane 1: XHindlll digest; Lane 2: 
pACYC/hybrid-1; Lane 3: pACYC/hybrid-l digested with 
Ncol and BamHI; Lane 4: pACYC/hybrid-2; Lane 5: 
pACYC/hybrid-2 digested with Ncol and BamHI; Lane 6: 
pACYC/hybrid-3; Lane 7: pACYC/hybrid-3 digested with 
Ncol and BamHI; Lane 8: pET/58210 digested with Ncol and 
BamHI (as a reference). 
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Fig. 3.25 Digestion of pET/MMC-TCS with various enzymes. 
Lane 1: digested with Pstl and Hhcd; Lane 2: 
digested with Pstl and Seal; ； Lane 3: digested 
with Ncol and BamUl; Lane 4: hybrid-15 before 
digestions; Lane 5: XHindlll digest. 
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3.2.2.2 EXPRESSION OF TCS/MMC CHIMERIC cDNA 
The cloned MMC-TCS chimeric cDNA was induced for 
expression in E. coli BL21 cells. It can be seen that the expression 
was quite efficient and a discrete band at an estimated molecular 
weight of 26000 Da in SDS-PAGE can be observed (Fig. 3.26). The 
expression of this clone could be monitored with anti-aMMC serum 
RB004 (Fig. 3.27). 
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Fig. 3.26 SDS-PAGE analysis of expression of MMC-TCS chimeric 
cDNA. Lane 1: Protein markers; Lane 2: aMMC; Lane 3: 
E. coli BL21 (DE3); Lane 4: E. coli with pET-8c only; 
Lane 5: E. coli with pET-8c induced by IPTG; Lane 6: 
E. coli with MMC-TCS chimeric plasmid; Lane 7: E. coli 
with MMC-TCS chimeric plasmid induced by IPTG. 
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Fig. 3.27 Western blot analysis of expression of MMC-TCS chimeric 
cDNA. Lane 1: aMMC; Lane 2 E. coli BL21 (DE3); 
Lane 3 E. coli with pET-8c only; Lane 4: E. coli with 
pET-8c induced by IPTG; Lane 5: E. coli with MMC-TCS 
chimeric plasmid; Lane 6: E. coli with MMC-TCS chimeric 
plasmid induced by IPTG. 
� 
141 
3.2.2.3 PURIFICATION OF MMC-TCS CHIMERIC PROTEIN 
The MMC-TCS chimeric protein was purified following the 
same procedure as for the recombinant aMMC, assuming that the 
physical properties of the chimeric protein were not much different. 
The elution pattern of the MMC-TCS chimeric protein on a CM-
Sepharose column is shown in Fig. 3.28. After elution, three major 
peaks were collected and monitored by SDS-PAGE (Fig. 3.29) and 
Western blotting (Fig. 3.30). Unexpectedly, the immuno-reactive 
fraction probably representing the presence of the chimeric protein 
was eluted in the unabsorbed fraction. Since our aim was to 
determine the epitopic fragments of aMMC, further attempts to purify 
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Fig. 3.28 Elution profile ofMMC-TCS chimeric protein on CM-Sepharose 
column. Buffer A: 10 mM sodium phosphate buffer pH 6.8; 
buffer B: 0.1 M NaCl in buffer A; buffer C: 0.5 M NaCl in buffer A. 
Three indicated peaks were collected. 
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Fig. 3.29 SDS-PAGE analysis of the column eluates of MMC-TCS 
chimeric protein. Lane 1: aMMC; Lane 2: peak 1; 
Lane 3: peak 2; Lane 4: peak 3; Lane 5: buffer 
A wash. 
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Fig. 3.30 Western blot analysis of column eluates of MMC-TCS 
chimeric protein. Lane 1: aMMC; Lane 2: peak 1; 
Lane 3: peak 2, Lane 4: peak 3; Lane 5: buffer 
A wash. 
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3.2.2.4 REACTIVITY OF MMC-TCS CHIMERIC PROTEIN WITH 
VARIOUS ANTISERA 
The immuno-reactivity of the MMC-TCS chimeric protein was 
tested using two different batches of anti-aMMC sera RB004 and 
RB006 and a batch of anti-TCS 87047 by Western blotting. The 
results of the reactions are summarized in Table 3.2: 
Anti-OfMMC RB004 Anti-aMMC RB006 Ant i -TCS 87047 
TCS + - + 
aMMC + + -
MMC-TCS + + -
c h i m e r i c 
p r o t e i n 
Table 3.2 Reactivity of MMC-TCS chimeric protein with various antisera. 
It can be seen that the antisera RB004 and RB006 raised 
against native aMMC could react with the chimeric protein, but an 
antiserum raised against native TCS could not react with this protein. 
In our study, one of the anti-aMMC sera, RB004, was found to cross-
react with TCS, suggesting that this antiserum could recognize 
epitopic sequences on TCS looking similar to aMMC. Since the anti-
TCS serum was not reactive with the chimeric protein, the TCS-





A chimeric cDNA of aMMC and TCS was constructed and 
expressed in E. coli. In this construct, a fragment in the central region 
of TCS was replaced by a corresponding aMMC sequence. 
It has been found that aMMC and TCS have very similar 
structure and biological functions, but have quite different 
antigenicities. In our study, the antigenicity of the MMC-TCS 
chimeric protein was tested with two anti-aMMC sera (RB004 and 
RB006) and one anti-TCS serum 87047 (Table 3.2 in Section 3.5.4). 
It is of interest that the aMMC-specific antiserum RB006 could react 
with the chimeric protein. This suggests that the epitopes recognized 
by RB006 may be present on the aMMC part of the protein. On the 
other hand, RB004 is less specific and could react with TCS. The 
cross-reactivity may be due to some epitopic sequences commonly 
shared by aMMC and TCS. Since the N-terminal parts of aMMC and 
TCS are known to have high sequence homology, it is suggested that 
these epitopic regions are present in the N-terminal sequence of these 
proteins. As the anti-TCS serum could not recognize the chimeric 
protein, the TCS-specific epitopes on the TCS molecule are likely 
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located in the fragment replaced by aMMC (Fig. 3.31). 
RB004 RB006 
CXMMC I ‘ ‘ 1 
RB004 87047 
TCS I ‘ ‘ 1 
RB004 RB006 
Chimeric | ‘ � ‘ n 1 
TCS cxMMC TCS 
N-terminal C-terminal 
Fig. 3.31 Schematic representation of the epitopic regions on aMMC, TCS 
and the MMC-TCS chimeric protein as revealed by various 
antisera. 
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CHAPTER 4 SCREENING OF aMMC IMMUNO-REACTIVE 
FRAGMENTS FROM A RANDOM 
FRAGMENT LIBRARY 
In the previous Chapter, the immuno-reactivity of truncated 
aMMC fragments has been studied with a set of aMMC fragments 
of different lengths with deletion from the C-terminal. It appeared 
that all the deleted aMMC fragments in the study were immuno-
reactive. The smallest fragment was found to represent the amino acid 
sequence 1-141. This suggests that at least one or more epitopic 
regions are present in this sequence. However, the possibility that 
there are other epitopic determinants present in the deleted part of the 
aMMC polypeptide cannot be ruled out. 
In order to test this possibility and determine the precise 
regions of the antigenic determinants in the aMMC molecule, we 
have constructed a random fragment library of this protein. In our 
study, aMMC cDNA was randomly cleaved to a size of 50-150 bp. 
These fragments were cloned and expressed as a fusion with T7 gene 
10 protein in E. coli. The library constructed in this manner was then 
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screened with an aMMC antiserum. Positive clones reacting with the 
antiserum were isolated and analysed by DNA sequencing. As only 
fragments carrying the epitope recognized by the antiserum would be 
detected, characterizing the insert sequence of the positive clones 
would enable us to map out regions of the aMMC molecule which 
are responsible for determinating antigenicity. 
� 
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4.1 MATERIALS AND METHODS 
4.1.1 DESCRIPTION OF THE pTOPE VECTOR 
The pTOPE vector was purchased from Novagen, USA. This 
vector is from the pET family and contains a high copy number 
origin of replication for better plasmid yields. This vector is pre-
digested with EcdRM and treated by addition of a single 3' dT residue 
at each end. Inserts having single 3，dA overhangs can then be 
ligated directly into this vector. The T-cloning site in pTOPE is 
placed in such a way that the target sequences are expressed as a 
fusion protein containing the first 260 amino acid residues of the T7 
gene 10 protein (Fig. 4.1). This fusion would provide high level 
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Fig. 4.1 Plasmid map of pTOPE 
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4.1.2 CONSTRUCTION OF AN aMMC RANDOM FRAGMENT 
LIBRARY IN E. coli 
In this research, a purified preparation of full-length aMMC 
cDNA fragment was partially digested by DNase I into small 
fragments averaging 50 to 150 bp in size. The fragments were 
separated by electrophoresis and isolated by electro-elution. The 
isolated fragments were treated with T4 DNA polymerase and Tth 
DNA polymerase to add a single dA residue to each 3' end. These 
prepared fragments were ligated by A-T cloning into the pTOPE 
vector (Novagen, USA) containing single dT overhangs. The vector 
allows the expression of small peptides in a form of fiision protein, 
which has an advantage of preventing the breakdown of fragments by 
cellular proteases. Expression in the pTOPE vector is controlled by 
a T7 promoter. For screening, ligation mixtures are transformed into 
E. coli lysogenized with the bacteriophage 入 DE3，which carries a 
copy of the T7 RNA polymerase gene under the control of the 
inducible lac\JWS promoter. Addition of IPTG to the growing culture 
would induce expression of T7 RNA polymerase and switch on the 
target gene carried in the plasmid. Colonies are transferred to a 
nitrocellulose membrane, lysed and screened with an aMMC 
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antiserum. Plasmid DNAs from positive clones were picked and 
sequenced for characterization of the clone (Fig. 4.2). 
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Fig. 4.2 Construction of random fragment library of aMMC 
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4.1.2.1 PREPARATION OF THE cDNA INSERT OF aMMC 
4.1.2.1.1 LARGE SCALE PREPARATION OF THE PLASMID 
MMC18p8 
A single colony of the E. coli JM109 containing MMC18p8 
was picked up from a fresh plate streaked from a stab culture or from 
a -70°C glycerol stock and inoculated into 150 ml of LB medium 
containing 50 |Lig ampicillin/ml. The culture was incubated overnight 
at ^TC in an orbital bath shaker at 300 rpm. The whole culture was 
then chilled at 4°C for 5 min, centrifuged at 5000 xg in a Hitachi 
SCR20B refrigerated high speed centrifuge at 4 � C for 15 min. The 
cell pellet was retained for plasmid preparation by the method of 
Qiagen (Appendix A.5). DNA concentration was determined by 
reading the OD260 of a 5 i^l sample in 500 |LI1 water (1 OD260 unit 二 
50 ]xg/m\). The yield of the DNA preparation was approximately 100 
|ig/150 ml culture. 
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4.1.2.1.2 DIGESTION OF THE PLASMID MMC18p8 
WITH Ecom 
To release the aMMC cDNA containing fragment, 100 |LI1 of 
the purified MMC18p8 DNA were mixed with 20 u of EcoRl (10 
|il)(Promega, USA), 15 |LI1 of 五CORI buffer (supplied with the enzyme 
from the manufacturer), and 15 |al of water. The digestion mixture 
was incubated at 37°C for 1.5 hr. After digestion, the mixture was 
heated at 70°C for 5 min, mixed with 30 |il of 6x agarose gel loading 
buffer, and loaded onto a 2-cm wide comb of 1.5% agarose gel in a 
submarine-type electrophoresis apparatus. Electrophoresis was carried 
out at a constant voltage of 80 V until the tracing dye (representing 
approximately 150 bp of length) had migrated 5 cm from the origin. 
For comparison, 2 |LI1 of the 123 bp standard markers (from BRL, 
USA) premixed with 6 |LI1 water and 2 |LI1 loading buffer was loaded 
on the adjacent lane. 
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4.1.2.1.3 ELECTRO-ELUTION 
After electrophoresis, the DNA band was viewed on a UV-
transilluminator and excised with a piece of scalpel blade. The 
excised agarose stick was transferred to a segment of dialysis tube 
(approximately 1.5 cm x 2 cm, pretreated by boiling in 10 mM 
EDTA) with a molecular weight cut-off of 12000 Da. The tube was 
filled with TBE buffer and sealed with a pair of closures at the ends. 
Bubbles in the tubes were carefully excluded by pressing the tube 
gently while sealing. The tube with the agarose stick was submerged 
in TBE buffer in a standard horizontal submarine gel tank. For 
electro-elution, the agarose stick was moved close to the side of the 
dialysis tube which was near the cathode, and the direction of the gel 
stick was perpendicular to the lines of the electric field. DNA was 
eluted at 80 V for 30 min. The degree of electro-elution was checked 
by viewing the dialysis bag on a UV-transilluminator. When electro-
elution was completed, the dialysis bag was put into the buffer again 
and electrophoresed for a further 30 sec by reversing the connections 
of the positive and negative electrodes. This would facilitate the 
dislocation of the DNA stuck on the bag. The DNA solution in the 
bag was transferred to a 1.5-ml microcentrifuge tube and extracted 
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with an equal volume of phenolxhloroformiisoamyl alcohol (25:24:1) 
and an equal volume of chloroformiisoamyl alcohol (24:1) 
respectively. DNA was precipitated by adding 0.1 volume of 3 M 
sodium acetate (pH 4.7) and 2 volumes of ethanol on ice for 30 min. 
The suspensions were then centrifuged at 12000 xg for 15 min, and 
the pellets were rinsed with 70% ethanol and dried briefly. The 
pellets were dissolved and pooled into 50 of TE buffer. 
4.1.2.2 DNASE I DIGESTION 
DNA digestion was carried out at various concentrations of 
DNase I to insure that the correct range of fragment size was 
obtained. DNase I was first diluted 133 fold by mixing 1 |LI1 of DNase 
I to 132 |Lil of a dilution buffer prepared by mixing 20 |iil of lOx 
MnCl2 (100 mM), 20 lOx DNase I buffer (0.5M Tris-HCl pH 7.5， 
0.5 mg/ml BSA) and 160 |LI1 sterile distilled water. A 1:200 dilution 
of the enzyme was further prepared by adding 30 |LI1 of this diluted 
solution to 15 Ml of the dilution buffer. Similarly, 1:300 and 1:450 
dilutions were prepared. 
� 
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Digestions were set up as follows in microcentrifuge tubes: 
Tube lOx DNase I buffer lOx MnCL aMMC DNA insert DNase I Water to 
1 0.9 [i\ 0.9 6 i^l (8-10 ug) 1 of 1:133 10 
2 0.9 i^l 0.9 i^l 6 i^l (8-10 ug) 1 i^l of 1:200 10 i^l 
3 0.9 |il 0.9 i^l 6 III (8-10 ug) 1 pi of 1:300 10 
4 0.9 0.9 [l\ 6 Hi (8-10 ug) 1 nl of 1:450 10 i^l 
The reaction was started by adding the enzyme and mixing 
gently. The tubes were incubated at 21°C for exactly 10 min. The 
reaction was stopped by adding 2 |LI1 of 6x stop buffer to each tube. 
The stop buffer contained 100 mM EDTA, 30% glycerol and tracking 
dyes. After the reaction, 1 |LI1 sample from each tube was taken and 
analysed on a 2% agarose gel. 
4.1.2.3 FRACTIONATION OF DNA FRAGMENTS 
4.1.2.3.1 ELECTROPHORESIS 
The digested DNA from the different reaction mix were pooled 
(36 |Lil) and loaded onto a 2% agarose gel. Five |LI1 of the PGR 
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marker standard (Novagen, USA) were loaded on the adjacent lane 
for comparison. Electrophoresis was carried out at 80 V for 45 min 
in TBE buffer. After electrophoresis, the DNA was visualized in a 
UV-transilluminator and the band was later cut out. 
4.1.2.3.2 ELECTRO-ELUTION 
The excised agarose stick was placed in a dialysis tube sealed 
with closures as described in Section 4.1.2.1.3. Electro-elution was 
carried out at 80 V for 30 min. Reverse elution was carried out for 30 
sec. After elution, the DNA containing solution was collected and 
extracted with an equal volume of phenol:chloroform:isoamyl alcohol 
(25:24:1) and an equal volume of chloroformiisoamyl alcohol (24:1), 
respectively. The extracted DNA was further precipitated by adding 
0.1 volume of 3 M sodium acetate (pH 4.7) and 2 volumes of 
ethanol. The precipitated DNA was washed with 70% ethanol, dried 
briefly, and dissolved in 30 i^l TE (pH 8.0). 
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4.1.2.4 SINGLE dA TAILING 
The DNase I-digested fragments from Section 4.1.2.2 were 
treated in consecutive reactions with T4 DNA polymerase and Tth 
DNA polymerase. This prepared for the DNA cloning into the 
pTOPE vector. The reaction components were as follows: 
DNA digested fragments of aMMC cDNA insert 10 |il (1 ^ig) 
lOx Flush buffer (0.5 M Tris-HCl pH 8.0， 2.5 i^l 
50 mM MgCl2，1 mg/ml BSA) 
lOx dNTP Mix (1 mM each dCTP, dGTP, dTTP, 10 mM dATP) 2.5 i^l 
20x DTT (100 mM) 1.25 i^l 
T4 DNA polymerase (1-2 units) 0.5 i^l 
Sterile 即 to 25 i^l 
The reaction was started by adding the enzyme. The mixture 
was incubated at 11°C for 20 min. The reaction was stopped by 
heating for 10 min at 75°C. After heat inactivation, the entire mixture 
was used for single dA tailing reaction. 
The reaction for dA tailing was as follows: 
DNA mixture from the above 25 pi (1 ^g) 
lOx dA Tailing Buffer (100 mM Tris-HCl pH 9.0， 8.5 
0.5 M KCl, 0.1% gelatin, 1% Triton X-100) 
Tth DNA polymerase (1.25 units) 0-5 
The reaction was started by adding the enzyme and mixing 
gently with a pipette tip. The mixture was incubated at 70�C for 5 
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min. After incubation, the mixture was extracted with 1 volume of 
chloroformiisoamyl alcohol (24:1)，and centrifuged at 12000 xg for 
1 min. The aqueous phase was transferred to a fresh microcentrifuge 
tube. The DNA was stored at -20°C if not used immediately. 
4.1.2.5 LIGATION 
The ligation reaction was set up as follows: 
lOx Ligation buffer (200 mM Tris-HCl pH 7.6，1 i^l 
50 mM MgCy 
100 mM DTT 0.5 
10 mM ATP 0.5 |LI1 
pTOPT T-vector (50 ng/jil, 0.03 pmol) 1 
T4 DNA ligase (2-3 Weiss units) 0.5 
DNA fragments 3 i^l 
(approx. 0.2 pmol or 5 ng of 100 bp DNA) 
Sterile HjO 3.5 i^l 
The reaction mix was incubated at 16°C overnight. 
4.1.2.6 TRANSFORMATION 
NovaBlue(DE3) competent cells were purchased from Novagen, 
USA. The competent cells were supplied as frozen stock. For 
transformation, 50-|LI1 aliquots of the frozen cells were thawn on ice 
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and added to the pre-chilled microcentrifuge tubes. Three |LI1 of each 
ligation mixture were added to the cells. The cells are stirred gently 
with a pipette tip and placed on ice for 30 min. The tubes were then 
heated for exactly 50 sec in a 42°C water bath, and placed on ice for 
2 min. Two hundred |il of SOC medium equilibrated at room 
temperature were added to each tube. The cell mixtures were further 
shaken at 200-250 rpm at 37°C for 1 hr to express the antibiotics 
resistant genes. After incubation, 150-|LI1, 100-|LI1 and 50-|LI1 aliquots of 
the transformation mixture were plated on LB agar plates containing 
50 |Lig/ml carbenicillin and 15 [ig/ml tetracycline. The plates were 
then incubated in an inverted position at 37°C overnight. 
4.1.2.7 CONTROLS 
4.1.2.7.1 FULL-LENGTH aMMC cDNA CONTROL 
As a control, a full-length aMMC cDNA was treated by the 
same procedure to create a single dA tailing. This modified fragment 
was cloned into pTOPE in parallel as a positive control. 
� 
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4.1.2.7.2 T-VECTOR LIGATION CONTROL 
This control was a synthetic 50-mer reaction control (Fig. 4.3) 
supplied with the pTOPE plasmid. The 50-mer already has a single 
dA in its ends. This control fragment was used to check the ligation 
efficiency. For ligation, 2 |LI1 (5 ng) of the control were used. 
5 ‘ ACAGCCTGAACTCGCTCCAGAGGATCCGGAAGATTAAGTGATTAAGTCATA 3, 
3 ‘ ATGTCGGACTTGAGCGAGGTCTCCTAGGCCTTCTAATTCACTAATTCAGTA 5, 
Fig. 4.3 The 50-mer Ligation Control 
4.1.2.8 STORAGE OF THE FRAGMENT LIBRARY 
E. coli transformed with the randomly cleaved fragments of 
aMMC cDNA were amplified by growing 50 |LI1 of the culture in 2 
ml of LB medium containing 50 |Lig/ml of carbenicillin and 15 |Lig/ml 
tetracycline at 37°C overnight. A 0.8-ml aliquot of the culture was 
mixed with 0.2 ml of glycerol in a 2-ml Cyrotube. The culture was 
quick frozen in liquid nitrogen and stored at -70°C. 
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4.1.3 IMMUNOSCREENING OF THE RANDOM FRAGMENT 
LIBRARY OF aMMC 
4.1.3.1 ANTI-aMMC SERA 
Anti-aMMC sera were obtained from Dr. Walter Ho and Dr. 
H.W. Yeung of the Department of Biochemistry, Chinese University 
of Hong Kong. The antisera were raised in rabbits using purified 
aMMC. For identification purposes, the two antisera against 
succinylated aMMC from Dr. Ho were designated RB004 and 
RB006, and an antiserum against native aMMC from Dr. Yeung was 
called YOOl. 
4.1.3.2 PURIFICATION OF ANTI-aMMC SERA 
Anti-aMMC sera have to be purified before they can be used 
for library screening. Antisera were either purified by affinity method 
or by adsorption method. 
For affinity purification, 0.5 g CNBr-activated Sephardse 
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(Pharmacia, Sweden) was swollen in 5 ml of 0.1 M phosphate buffer 
(pH 7.4), and mixed with 2 mg of aMMC. The suspension was 
incubated at room temperature for 1 hr and packed into a small 
Econo column (Bio-rad). The column was washed with 10 bed 
volumes of PBS, then loaded with 100 |LI1 of an anti-aMMC serum. 
The loading was repeated 2 times to increase the binding. The column 
was washed twice with 5 ml of PBS and the antibody was eluted with 
1 ml of 0.1 M acetic acid, pH 4.0. The eluted antibody was dialysed 
against 0.1 M phosphate buffer, pH 7.4. 
For adsorption purification, several sheets of nitrocellulose 
paper with dimensions of about 5cm x 5cm were saturated with the 
NovaBlue E. coli lysate (prepared as follows) and washed briefly 2 
times with TEST (10 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.5% 
Tween-20). 50 ml of anti-aMMC serum diluted 1000 fold with TEST 
was incubated with 2 pieces of the pre-treated Whatman paper in a 
petri dish and agitated in an orbital shaker at 150-200 rpm for 1 hr. 
After shaking, the Whatman paper were removed and replaced with 
2 pieces of new pre-treated paper. Shaking was continued for 1 hr. 
The process was repeated with a total of 4 changes of paper. After 
this treatment, the antiserum was ready for screening. In most cases, 
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the E. coli lysate-treated antisera were found to be good enough for 
screening. 
Preparation of the E. coli Lvsate 
Antisera for use in library screening were treated with the E. coli 
lysate to remove IgG components contained in the antisera that can 
bind to E. coli proteins. To prepare the lysate, 150 ml of an 
overnight culture of NovaBlue E. coli was centrifuged at 500 xg for 
10 min. The pellet was re-suspended in 50 ml of 50 mM Tris-HCl pH 
8.0. Lysozyme was added to a final concentration of 100 |Lig/ml. The 
whole suspension was left at room temperature for 1 hr. DNase I was 
then added at a final concentration of 10 |Lig/ml. The suspension was 
further incubated at room temperature for 2 hr. 
4.1.3.3. COLONY LIFT 
E. coli transformed with plasmids carrying random fragments 
of aMMC cDNA were plated on an LB agar plate containing 50 
l^g/inl carbenicillin and 15 |ig/ml tetracycline. The source of bacteria 
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was either from a fresh transformation mixture or from a library 
stock. Cells were normally plated to a density of 2000-5000 colonies 
in an 82-mm petic dish. The bacteria were grown at 37�C for 10 hr. 
At this point, the size of the colonies was 0.5-lmm in diameter and 
the colonies were ready for screening. 
Prior to colony lift, the plate was removed from the incubator 
and chilled for 30 min at 4°C to prevent sticking of the agar onto the 
nitrocellulose membrane. In a sterile hood, the agar plate was 
carefully overlaid with a sheet of sterile nitrocellulose membrane 
(82mm in diameter, Millipore) with the centre of the membrane 
touching the agar first. The membrane was marked by punching 3 
asymmetric small holes with an 18-guage needle through the 
membrane into the agar. The membrane was then carefully peeled off 
after it was totally wetted. The plate was returned to 37°C for 4 hr to 
regenerate the colonies. 
168 
4.1.3.4 INDUCTION OF EXPRESSION 
The fusion aMMC cDNA fragments were induced to express 
by putting a nitrocellulose membrane containing 0.4 mM IPTG (with 
colony side up) on an agar plate and incubated at 37°C for 1 hr. The 
plate was loosely covered to prevent the colonies from drying. 
4.1.3.5 COLONY LYSIS 
After induction, colonies were lysed by putting the 
nitrocellulose membrane into a chloroform vapour chamber for 15 
min. The filter was then removed and placed colony side up on a 
piece of Whatman 3 mm paper saturated with denaturing solution (20 
mM Tris-HCl, pH 7.9, 6 M Urea, 0.5 M NaCl) for 15 min at room 
temperature. After denaturation, the filter was removed and shaken 
with 10 ml of lysis buffer (100 mM Tris-HCl pH 7.8, 150 mM NaCl, 
5 mM MgCl2，1.5% BSA，1 |Lig/ml DNase I，40 ^ig/ml lysozyme) 
with colony side up for 10-16 hr at room temperature. Remaining cell 
debris on the membrane was further removed by washing with 10 ml 
of TEST for 15 min and rumbed with a piece of Kimwipe tissue. 
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4.1.3.6 IMMUNOSCREENING 
The nitrocellulose membrane was agitated with 10 ml a 1000-
fold diluted anti-aMMC serum for 2 hr. The membrane was washed 
3x10 min with TEST, then 10 ml of a secondary antibody linked with 
alkaline phosphatase (Bio-RAD) diluted 2000 fold with TEST was 
added. The membrane was agitated at room temperature for 2 hr, and 
washed with 3x10 min TEST. To develop signals, 10 ml of staining 
solution (0.1 ml ofBCIP-Na salt (5 mg/ml in 即)，1 ml of nitroblue 
tetrazolium (1 mg/ml in 0.15M barbital buffer, pH 9.4), 0.02 ml of 2 
M MgCl2 were added. The reaction was allowed to continue for 10 
to 30 min for colour development. 
4.1.4 PCR SCREENING OF INSERTS 
PCR screening for the presence of inserts was performed either 
on the purified plasmid DNAs or on the bacterial colonies directly. 
For plasmids, plasmid DNAs from positive clones were prepared by 
the standard procedure using Magic Prep kit from Promega 
(Appendix A.4). The DNA samples were diluted to a concentration 
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of 1 ng/|LIL Five |LI1 of each sample were used for PCR. For bacteria, 
a positive colony (about 1 mm in diameter) was transferred to 50 |LI1 
of sterile water in a microfuge tube and mixed. The suspension was 
boiled for 5 min to lyse the cells and denature DNases，and 
centrifuged at 12000 xg for 1 min. Ten |LI1 of the supernatant was 
used for PCR with the following primers (Fig. 4.4). In a 0.5-ml 
microfuge tube, the following PCR mix was prepared: 
DNA 5 or 10 i^l 
lOx PCR buffer 5 i^l 
dNTP mix (2mM each) 5 |LI1 
T7 gene 10 primer (20 ng/fil) 1 
T7 termination primer (20 ng/|il) 1 [il 
Taq DNA polymerase 0.5 |LI1 
Sterile H'O to 50 |LI1 
T7 gene 10 primer (19 bp)： 
5' TGA GGT TGT AGA AGT TCC G 3' 
T7 termination primer (19 bp)： 
5' GCT AGT TAT TGC TCA GCG G 3' 
Fig. 4.4 Sequences of the PCR primers 
The contents of the PCR mix were briefly agitated by vortex 
and concentrated to the bottom of the tube by brief centrifugation. 
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Before PCR, 30 |LI1 of mineral oil was layered on top of the reaction 
mixture. 
PCR was carried out in a Pharmacia Thermocycler for 35 
cycles of 1 min at 94°C, 1 min at 55°C, and 2 min at TTC, with the 
first denaturation step at 94°C for 7 min and the final extension step 
at 72°C for 10 min. Ten |LI1 of the reaction products were used for 
analysis on a 1% agarose gel containing 0.5 [ig/ml ethidium bromide. 
4.1.5 AMPLIFICATION OF POSITIVE SIGNALS 
The potential positive clones were amplified by picking and re-
plating them on new LB agar plates containing 50 |Lig/ml carbenicillin 
and 15 |ig/ml tetracycline. The plates were incubated in an inverted 
position overnight at 37�C and re-screened for immuno-signals as 
described before (Section 4.1.3.3). 
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4.1.6 DOT BLOT 
In certain cases, dot blot was used as a preliminary screening 
procedure for a large number of clones. The purpose of this procedure 
was to reduce the number of clones for handling. Positive clones 
determined by dot blot were required to be re-confirmed by Western 
blot. 
For dot blot, an overnight culture of a positive clone in LB 
containing 50 |Lig/ml carbenicillin and 12.5 |ig/ml tetracycline was 
harvested. Cell pellet was suspended in 60 |il 4% SDS，sonicated for 
2x15 sec on ice, boiled for 5 min in a water bath, and centri&ged for 
5 min in a microcentrifuge to remove precipitate. Two-|il aliquots of 
the supematants or standard aMMC (0.1 mg/ml) were spotted on a 
sheet of nitrocellulose paper. The paper was dried briefly in air and 
blocked with 5 ml 4% non-fat milk in TEST for 1 hr at room 
temperature. After blocking, the procedure of detection was the same 
as that of Western blot (Section 4.1.7). 
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4.1.7 CONFIRMATION OF POSITIVE SIGNALS BY 
WESTERN BLOT 
Potential positive clones were further confirmed by Western 
blot in order to differentiate false from positive signals. 
For Western blot, bacterial samples from potential positive 
clones were inoculated into 2 ml of LB containing 50 |ig carbenicillin 
and 25 |Lig/ml tetracycline and shaken at 37�C overnight. IPTG was 
added to each culture tube to a final concentration of 0.4 mM and 
shaking was continued for 2 hr at 37°C to induce expression. 
Bacterial cells were harvested by centrifiigation. The pellets obtained 
were suspended in 50 of SDS-PAGE loading buffer and sonicated 
for 3x15 sec on ice. The samples were then boiled for 5 min and 
centrifuged for 5 min in a microcentrifuge. The samples prepared in 
this manner were then separated on a 12.5 % SDS polyacrylamide gel 
(Section 2.1.1.10). 
After electrophoresis, the protein bands were transferred to a 
nitrocellulose paper as described in Section 2.1.1.11. After the 
transfer, non-specific binding sites on the nitrocellulose were blocked 
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by treatment with 10 ml 4% skimmed milk in TEST for 1 hr. After 
blocking, the paper was washed 3x10 min with TEST, and shaken 
with 10 ml anti-aMMC serum (1:1000 diluted in TEST) at room 
temperature for 2 hr. The paper was then washed with TEST for 3x10 
min, and shaken with 10 ml of protein A-peroxidase solution (1 |Lig 
of protein A-peroxidase conjugate in 5 ml TEST) for 30 min at room 
temperature. After shaking, the paper was washed for 2x10 min with 
TEST and reacted with an ECL chromogenic reagent (1:1 v/v mixture 
of the Amersham ECL reagents 1 and 2) for 1 min at room 
temperature. The paper was then placed on a transparent film with the 
edges breifly fixed by Cellotapes. The whole film was wrapped by a 
Saran sheet and, in the dark, placed on a Kodak X-ray film to expose 
for 5 sec. The film was developed in a Kodak developer for 5 min 
and fixed in a Kodak fixer for 10 min. 
4.1.8 ANALYSIS OF POSITIVE CLONES BY DNA 
SEQUENCING 
Plasmid DNA from positive clones were prepared by Magic 
Prep (Promega, USA). The DNA sequences of the aMMC random 
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fragments were determined as described in Appendix A.l using the 
T7 gene 10 forward primer approximately 100 bp upstream from the 
cloning site. 
4.1.9 ANALYSIS OF 3-DIMENSONAL STRUCTURE OF aMMC 
The sequences of immuno-reactive fragments of aMMC were 
mapped and located on a 3-dimensional model of the molecule 
constructed with a set of X-ray diffraction data for native aMMC 
(Data provided by Prof. Y.C. Dong, Institute of Biophysics, Academia 
Sinica，China). Analysis was done with the help of the software 
QUANTA (Polygene, USA) on a Silicon Graphics Workstation. 
4.1.10 EFFECT OF A MONOCLONAL ANTI-aMMC (#A1) ON 
RIBOSOME-INACTIVATING ACTIVITY OF aMMC 
A set of 10 monoclonal aMMC antibodies produced by the 
method of Kohler and Milstein (1975) was provided by Dr. Walter 
Ho. The antibody #A1 was obtained by screening the monoclonals 
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with the immuno-reactive clone 401 by Western blotting. The assay 
of ribosome-inactivating activity was carried out in two groups. In 
Group A， the assay was performed by the same procedure as 
described in Section 2.1.1.12. A control containing 0.5 mg/ml BSA 
without aMMC was treated as 100% protein synthesis for this group. 
Group B was similar to Group A except that the assay was performed 
in the presence of 0.5 mg/ml monoclonal aMMC antibody #A1 added 
before incubation with the rabbit reticulocyte lysate. The control in 
this group contained 0.5 mg/ml #A1 without aMMC. The assay was 
carried out in triplicates. Data were expressed as percent of in vitro 
protein synthesis relative to the corresponding control. 
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4.2 RESULTS 
4.2.1 THEORETICAL CONSIDERATIONS 
Theoretically, the number of clones required for a given 
sequence present in a gene library can be calculated by the following 
formula (Sambrook et al., 1989): 
N= In (l-Py In (1-F) 
where 
N: Number of clones requires 
P： desired probability of finding the sequence (In this study, P=0.99) 
F: Fractional portion (ratio of length of target sequence to 
length of total sequence. In this stuty, the minimum length 
of target sequence is 50 bp, and the length of total 
sequence is approximately 1100 bp). 
Hence, N= (1-0.99)/ In (1- 50/1100) = 98.99 
In order for the the random fragments of aMMC to be 
expressed in the pTOPE plasmid, there are two possible orientations 
and three possible reading frames to consider. Hence, in the above 
calculation, N needs to be multiplied by 6 to take these possibilities 
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into consideration. Therefore, the theoretical number of clones 
required for screening a target sequence should be approximately 600. 
From the practical point of view, a library size of 2000-5000 
bacterial colonies would be enough for epitope screening. In our 
study, screening was performed on an 82-mm diameter nitrocellulose 
filter with 2000-3000 bacterial colonies. In order to detect all the 
possible epitopic fragments, we screened the library with three 
different anti-aMMC sera 2 to 10 times. In each screening, 10 to 30 
potential positive clones were taken and confirmed by re-plating and 
Western blotting. The results of our screening are summarized in 
Table 4.1. 
Anti-aMMC sera 
RB004 RB006 YOOl 
No of clones screened >20000 >5000 >5000 (10 screens) (2 screens) (2 screens) 
No. of potential positive >100 30 30 
clones picked up in the 
first screening 
No. of positive clones 7 0 2 
confirmed by Western blot 
Table 4.1 Summary of screening experiments 
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4.2.2 CONSTRUCTION OF A RANDOM FRAGMENT LIBRARY 
OF aMMC cDNA 
A random fragment library was generated by cloning a set of 
randomly digested fragments of aMMC cDNA fragment into the 
pTOPE fusion vector. Expression of the fragments inserted into this 
vector would generate a set of fusion peptides which may be used to 
study the antigenic properties of the parent molecule. 
For library construction, the aMMC cDNA inserted in a pUC18 
vector (MMC18p8) was isolated by digestion with EcoRI and purified 
by electro-elution following gel separation (Fig. 4.5). 
The isolated aMMC cDNA fragment was partially digested by 
DNase I (Fig. 4.6), and the fragments with sizes between 50 to 150 
bp were collected. These fragments were cloned into the the pTOPE 
vector in which the fragments were fused to the gene coding for the 
protein T7 gene JO. Expression was induced and the individual 
clones were screened with an anti-aMMC serum for the presence of 




_ cDNA • : 
123 bp 
Fig. 4.5 The purified aMMC cDNA insert fragment before 
DNase I digestion. Lane 1: 123 bp DNA markers; 
Lane 2: The purified aMMC cDNA insert. 
181 
1 2 3 4 5 
- H ^ ^ ^ ^ H ^ H H 
300 - ^ ^ ^ I 
150 — ^ ^ ^ ^ ^ ^ ^ I h H ^ ^ H 
5 � -
Fig. 4.6 Partial Digestion of aMMC cDNA Insert by 
DNase I. Lane 1: DNA markers; Lane 2: 
aMMC cDNA partially digested by DNase I 
with DNase I dilution 1:133; Lane 3: DNase I 
dilution 1:200; Lane 4: DNase I dilution 1:300; 
Lane 5: DNase I dilution 1:450. Detailed 
procedures are described in the text. 
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4.2.3 SCREENING FOR IMMUNO-REACTIVE FRAGMENTS 
OF aMMC 
The aMMC random fragment library constructed as described 
in Materials and Methods was allowed to grow to pin-head size 
colonies on agar plates and subsequently transferred to 82-mm 
nitrocellulose membranes by lifting. The membranes were screened 
for immuno-reactive signals using anti-aMMC sera RB004, RB006 
and YOOl. To reduce noise level, these antisera were pre-adsorbed 
as described in Materials and Methods. The non-specific background 
in our screening was greatly reduced by the procedure (Fig. 4.7 and 
4.8). Positive clones identified in the first screening were amplified 
by re-plating the colonies and repeating the screening. Normally, if 
the clone picked was genuinely positive an enrichment of positive 
signals could be observed at this stage (Fig. 4.9). The presence of an 
epitopic fragments in these clones could be further confirmed by 
Western blotting. False positives would fail to give signals in this 
assay. 
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Fig. 4.7 Screening of Random Fragment Library of aMMC with 
Crude Antiserum RB004. High background was observed 
due to the non-specific interaction of E. coli proteins 
with the antiserum. 
Fig. 4.8 Screening of Random Fragment Library of aMMC with 
Purified Antiserum RB004. The number of non-specific 
signals was greatly reduced to a resonable level. 
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Fig. 4.9 Amplication of positive signal by re-plating. 
�� 
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4.2.4 CONFIRMATION OF POSITIVE SIGNALS BY 
WESTERN BLOTTING 
The positive clones obtained from the first screening were 
confirmed by Western blotting. Using this criterion, nine positive 
clones were obtained when our library was screened with the anti-
aMMC serum RB004 and two with antiserum YOOl. No signals 
could be obtained with RB006 (Table 4.1 in Section 4.2.1). The 
blotting results of these clones are shown in Figs. 4.9, 4.10, 4.11 and 
4.12. Since the size of the aMMC random fragments ranged from 16 
to 50 amino acid residues and they were fused to the gene 10 protein 
(283 amino acid long), the expected size of the fusion proteins would 
be around 36000 Da. 
As indicated in Fig. 4.10, the immuno-reactive clones exhibited 
a very strong signal in the blot when compared to other non-positive 
clones. In some blotting experiments, the amount of the fusion protein 
was overloaded, causing a smear in the blot. Nethertheless, the 
immuno-reactive band associated with the positive clones were 
obvious and easy to identify. 
�� 
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Fig. 4.10 Western blot analysis of antigenic fragments of aMMC. 
Lane 1: Natural aMMC; Lane 2: Clone 401; Lane 3: 
Clone 402; Lane 4: Clone 403. Lanes 5 to 7 ： same as 
clones 401 to 403 but 1/10 dilution, respectively. 
The first digit in the clone numbers represents the 
antiserum used for screening, i.e. RB004. Other 
digits are the serial numbers. Clones 401 and 403 were 
positive both in re-plating and in Western blot. In 
Western blot，a strong signal (indicated by an arrow) 
from these clones can be identified. In contrast, 
clone 402 failed to amplify signals by re-plating. No 
signal for this clone in the corresponding position by 
Western blotting can be observed. This clone is therefore 
treated as a negative clone. 
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4.2.5 ESTIMATION OF FRAGMENT SIZES BY PCR 
The potential positive clones in the first screening were 
analysed by PCR to confirm the existence of an insert and to estimate 
its size. In the absence of an insert, PCR amplifies a 212 bp fragment 
of the T7 gene 10 protein. Since the random fragments were 
expressed as a fusion protein with the T7 gene 10, the size of the 
aMMC fragments would be the measured size minus 212 (Fig. 4.11). 
From the results of PCR, the approximate size of the inserts was 300 
to 400 bp long. It is noted that the purpose of this analysis is only for 
preliminary estimation of the fragment size, detailed information of 
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Fig. 4.11 Estimation of the fragment sizes by PCR. Lane 1: 123-bp 
DNA markers. Lane 2: Clone 401; Lane 3: Clone 403; 
Lane 4: Clone 404, Lane 5: Clone 405; Lane 6: 50-mer 
positive control; Lane 7: H�� i n s t ead of DNA (negative 
control); Lane 8: PCR markers; Lane 9: Clone 410; 
Lane 10: Clone 411; Lane 11: Clone 407; Lane 12: Clone 
415; Lane 13: Clone 416; Lane 14: 123-bp markers. 
Clones 405 and 411 were later found to be a false 
positive clone in Western blotting. 
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4.2.6 ANALYSIS OF THE FRAGMENT SEQUENCES 
The insert of clones carrying immuno-reactive aMMC fragment 
was analysed by DNA sequencing. Based on the information 
obtained, the corresponding amino acid sequences could be deduced. 
A summary of the results of the nine positive clones characterized by 
DNA sequencing is shown in Fig. 4.12. The DNA sequences of 
seven immuno-reactive clones screened by RB004 and two by YOOl 
were determined. It was found that all of the immuno-reactive 
aMMC fragments were fused in-frame to the T7 gene 10 protein. In 
most of the clones (except clone 407)，a termination signal could be 
found after the insert sequence. The length of the immuno-reactive 
fragment was between 14 and 45 amino acids long. 
From the sequencing results, a linear schematic map of the 
epitopes of aMMC was constructed (Fig. 4.13). It is noted that there 
are three distinct epitopic regions on the aMMC molecule as revealed 
by matching the fragment sequence with the protein. The first region 
(aal-14，referring to the amino acid residue number on the mature 
aMMC) is located at the N-terminal portion of the molecule. 
Epitopes associated with this region were carried in clones Y08 and 
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Y12; both of which were detected by antiserum YOOl. Since these 
two clones have the same DNA sequence, they might have come 
from the same colony. The second region (aa71-136) located near the 
middle of the protein is defined by five clones screened with RB004. 
In this region, the sequences of the immuno-reactive fragments are 
overlapping to various degrees. The intense overlaps were found 
between aa89 and aal32. The third region (aal95-222) defined by 
two clones screened with RB004 was found near the C-terminal. The 
immuno-reactive fragments of these two clones have a similar 




一 pTOPE ~ I I M M C cDNA 406-480 1 | ~ pTOPE 2 7 bp 
Clone 401 TTC TGC AGA / TCT GGC AAT ... GCG TTG AAT / CAT CAC ACT TAA 3' 
Phe Cys Arg Leu Gly Asn Ala Leu Asn His His Thr *** 
108 109 110 130 131 132 
(25 amino acids) 
pTOPE 1 I MMC cDNA 343-492 1 � p T O P E 3 0 bp 
Clone 403 TTC TGC AGA TTT / GCT GCT GAA • . . GTG CAA TAA / ATC ATC ACA TAA 3' 
Phe Cys Arg Phe Ala Ala Glu Ser Ala lie Asn His His *** 
87 88 89 134 135 136 
(30 amino acids) 
pTOPE 1 I MMC cDNA 319-414 1 | p T O P E ^ ‘ ‘ 81 bp 
Clone 404 TTC TGC AGA TTC / ACA TCC TAC ... TCT GGC AAT / CCA TCA CAC TAG 3' 
Phe Cys Arg Phe Thr Ser Tyr Ser Gly Asn Pro Ser His *** 
79 80 81 108 109 110 
(32 amino acids) 
——pTOPE I I MMC cDNA 349-483 | | unknown insert 
Clone 407 TGC AGA TTT / GAA TTA GCT … T T G GAT / GGAT . . . TCTCT … 3 ' 
Cys Arg Phe Glu Leu Ala Leu Asp 
89 90 91 132 133 
(45 amino acids) 
——pTOPE ~ I I MMC cDNA 667-730 1 | p T O P E — 
Clone 410 TGC AGA TTT / CTC TCC AAA TGC TTG / TGA ATC ATC 3' 
Cys Arg Phe Leu Ser Lys Cys Leu *** 
195 196 197 215 216 
(21 amino acids) 
pTOPE 1 r— MMC cDNA 295-366 1 � p T O P E 81 bp 
Clone 415 TTC TGC AGA TTC / ATT ATG CAA TAT / GAA TGG ATC TAA 3' 
Phe Cys Arg Phe lie Met Gin Tyr Glu Trp H e *** 
71 72 93 94 
(24 amino acids) 
pTOPE 1 r— MMC cDNA 697-750 1 � p T O P E 30 bp 
Clone 416 TTC TGC AGA TTC / AAT AAT AAT CGA / ATC CAT CAC TAA 3' 
Phe Cys Arg Phe Asn Asn Asn Arg H e His His *** 
205 206 221 222 
(18 amino acids) 
pTOPE —1 I— MMC cDNA 85-126 —| | p T O P E 21 bp 
Clone Y08 TGC AGA TTT / ATT GTC AAA GGC GAT GTT TCC TAT / AAT CAT TAA 3' 
Cys Arg Phe lie Val Lys Gly Asp Val Ser Tyr Asn His *** 
1 2 13 14 
(14 amino acids) 
pTOPE —I |— MMC cDNA 85-126 —| |——pTOPE 21 bp 
Clone Y12 TGC AGA TTT / ATT GTC AAA GGC GAT GTT TCC TAT / AAT CAT TAA 3' 
Cys Arg Phe lie Val Lys Gly Asp Val Ser Tyr Asn His � *** 
1 2 13 14 
(14 amino acids) 
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/ \ \ \ \ \ \ \ Clone 416 (205-222) 
\ \ \ \ \ Clone 401 (108-132) \ 
\ \ Clone 404 (79-110) \ \ \ 
Clone Y12 (1-14) \ \ \ \ \ 
\ \ \ Clone 410 (195-216) 
Clone Y08 (1-14) \ \ Clone 403 (87-136) 
Clone 415 (71-94) \ 
Clone 407 (89-133) 
Fig. 4.13 Linear map of antigenic regions of aMMC. 
The antigenic regions of aMMC were determined by screening the random 
cleavage fragments of aMMC cDNA expressed in E. coli with anti-aMMC 
sera RB004 (clones 401，403，404, 407, 410，415 and 416) and YOOl (clones 
Y08 and Y12). The amino acid sequences were deduced by sequencing the 
aMMC cDNA fragments. The numbers in parentheses represent the amino 




4.2.7 CROSS-REACTIVITY OF THE IMMUNO-REACTIVE 
FRAGMENTS 
The random fragment library generated in the present study has 
been screened with three different anti-aMMC sera. Seven immuno-
positive clones were identified with antiserum from RB004 and two 
with antiserum YOOl. No positive clones could be detected with 
antiserum RB006. To find out as much as possible which fragment 
of aMMC is immuno-reactive, we screened the set of positive clones 
at hand with three antisera against aMMC (RB004, RB006, YOOl) 
and one against TCS (#87047) by Western blotting (Table 4.2). 
Anti-aMMC Anti-OfMMC Anti-aMMC Anti-TCS 
RB004 RB006 YOOl 87047 
Immuno-reactive clones 
401 + - + -
403 + - + -
404 + � + “ 
407 + - + -
410 + + + -
415 + - + -
416 + + + -
Y08 + + + -
Y12 + + + -
Recombinant 
Full-length ofMMC + + + -
Full-length TCS + - + + 
Natural 
aMMC + + + -
TCS + - + + 
BL21(DE3) Lysate -
(as a control) 
Table 4.2 Reactivity of the immuno-reactive fragments with 
various antibodies. � 
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All the positive clones were reactive against RB004 and YOOl, 
suggesting that these two sera have a similar set of epitopes 
recognizing antibodies. On the other hand, only the clones 410, 416, 
Y08 and Y12 were found to react with antiserum RB006. The 
selectivity of this antiserum suggests that it contains antibodies 
recognizing only the epitopes associated with the C- and N-terminal 
region. Because of this narrower range of recognition, it is not 
surprising that no immuno-reactive clones could be picked up by this 
serum. 
Since aMMC is similar to TCS, there is a possibility that there 
are fragments in aMMC which might be recognized by anti-TCS. An 
anti-TCS serum was included in the present test to map out 
topological regions of aMMC looking similar to TCS. As indicated 
in Table 4.2, neither the immuno-reactive fragments nor the fiill-
length aMMC could react against the anti-TCS serum. However, 
natural and recombinant TCS could be recognized by the two antisera 
raised against aMMC. This suggests that TCS may have some 
epitopic region looking similar to aMMC while no region in aMMC 




4.2.8 EFFECT OF A MONOCLONAL ANTI-aMMC (#A1) ON 
RIBOSOME-INACTIVATING ACTIVITY OF aMMC 
In our study, the monoclonal aMMC antibody #A1 reacts 
specifically with the clone 401 and this clone represents an immuno-
reactive region close to the proposed active site of aMMC (Section 
4.3), it is therefore interesting to see if this antibody can block the 
ribosome-inactivating activity. The effect of the monoclonal anti-
aMMC #A1 on in vitro protein synthesis inhibiting activity of 
aMMC is shown in Fig. 4.14. About one hundred fold decrease in 
the activity of aMMC was observed in the presence of the antibody 
at 0.5 mg/ml. This observation suggests that the interaction between 
this monoclonal antibody and aMMC elicits a significant inhibiting 
effect on aMMC's ribosome-inactivating activity. Since region B was 
found to be located at the opening of the proposed cleft in aMMC 
responsible for ribosome inactivation, it is not surprising that binding 
of the antibody onto this region would produce a steric hindrance on 
the active site residues. Because of this, protein synthesis inhibiting 
activity of aMMC is reduced. 
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Fig. 4.14 Effect of monoclcHial anti-aMMC (#A1) on ribosome-inactivating 
property of aMMC. Results are expressed as percent inhibition 
of/•« vitro protein synthesis relative to control. A significant 
decrease in activity of aMMC was found in the presence of 





A library containing small random fragments of aMMC cDNA 
averaging 50-150 bp long was constructed. In order to reveal the 
immuno-reactive fragments of aMMC, the library was screened with 
several polyclonal anti-aMMC sera. It was hoped that an epitope not 
recognized by one antiserum may be revealed by another. A 
summary of the screening experiments is presented in Table 4.1 
(Section 4.2.1). After repeated screening, nine immuno-reactive 
fragments of aMMC were found (Fig. 4.15). Seven of these 
fragments were revealed by screening the library with antiserum 
RB004 and two with antiserum YOOl. No immuno-reactive signals 
could be obtained with RB006 in our experiments. This may be due 
to the low recognition frequency of this antiserum (Section 4.2.1), 
and/or the regions recognized by this antiserum are weak epitopes. 
These immuno-reactive fragments represent three major regions 
on the aMMC polypeptide chain. The first region with amino acid 
sequence positions 1-14 (region A) is near the N-terminal, the second 
region with sequence positions 71-136 (region B) is located in the 
� 
middle of the polypeptide, and the third region with sequence 
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positions 195-222 (region C) is close to the C-terminal. 
A preliminary study using a region B-specific monoclonal 
aMMC antibody revealed that this antibody is able to cause a 100-
fold decrease in ribosome inactivating activity of aMMC. This is 
logical as the antibody binding region is located just outside the 
active site. Whether the antibody blocks the substrate from 




CHAPTER 5 GENERAL DISCUSSION 
The antigenic regions of some ribosome-inactivating proteins 
have been proposed. Gu et al (1986) have estimated the number of 
antigenic determinants on the TCS molecule by using antibody 
competitive binding assay. The principle of their assay is based on the 
competition of two monoclonal antibodies against the same 
determinant. Based on the data of this assay, they proposed that there 
are four different epitopes present on the TCS molecule. 
Unfortunately, they were unable to determine the exact position of 
these epitopes. Ke et al (1988) have obtained and identified two 
large fragments of TCS by partial digestion with chymotrypsin and 
found that these two fragments, located at sequence positions 79-234 
and 107-234, were immuno-reactive. Since it was difficult to obtain 
specific small fragments by this method, the precise location of these 
antigenic regions was not determined. 
The structure-function relationship of a protein can now be 
studied by expression of a gene encoding the full-length or selected 
� 
sequences of this molecule. This approach has been used to 
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determine fragment sequences of aMMC which are responsible for 
eliciting antigenicity. In our study, the precise antigenic regions of 
aMMC were determined, and the correlation of these regions with the 
structural topology of aMMC was investigated. 
In our study, the full-length aMMC cDNA was successfully 
expressed as a protein A-fusion and an unfused protein in E. coli. 
Although the cleavage and purification of the protein A-aMMC 
fusion was not satisfactory, the unfused recombinant aMMC was 
purified to homogeneity. The purified recombinant aMMC was 
found to be immuno-reactive with an antiserum raised against native 
aMMC and biologically active on in vitro inhibition of protein 
synthesis in the rabbit reticulocyte lysate system. Results of these 
experiments suggest that the recombinant aMMC has similar 
properties to the native protein. This full-length recombinant aMMC 
would provide the backbone for additional studies of various 
functions of the molecule. 
To determine the antigenic regions of aMMC, a set of deletion 
fragments of aMMC cDNA were expressed as a protein A-aMMC 
� 
fusion. Unfortunately, the cleavage and purification of these 
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recombinant fusion fragments were unsatisfactory and we could not 
continue our study with these constructs. Originally, we have opted 
for this approach because the protein A part of the aMMC fusion 
would provide a ligand for the affinity purification of the fragments. 
Although, by Western blot analysis, we have obtained evidence to 
indicate the fusion aMMC fragments did express, however, we could 
not purify them by IgG affinity chromatography because they did not 
bind to the column. The reason why a shortened fragment of aMMC 
could change the affinity of the protein A moiety for IgG remains to 
be determined. In view of the difficulties in working with the fusion, 
the truncated aMMC cDNA fragments were then expressed in a non-
fused system. With this system, four recombinant aMMC fragments 
with amino acid positions 1-141, 1-179，1-191 and 1-209 were found 
to be immuno-reactive. This suggests that at least one epitopic region 
is present in the minimum sequence of amino acid 1-141. Whether 
there are other epitopes outside this region cannot be ruled out in 
these experiments. 
To further determine the precise antigenic regions and correlate 
their topology positions on the aMMC molecule, a library of random 
fragments of aMMC cDNA was constructed and expressed mE. coli. 
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The library was screened by three antisera raised against two forms 
of aMMC. It has been found that antibodies against a defined 
epitope can give information about the accessiblity of the region in 
a given protein (Serrano et al” 1993). The sequence information of 
the immuno-reactive clones in a random fragment library can also be 
used to predict the structural topology of this protein (Miroux et al., 
1993). 
In our study, three separate epitopic regions were found in 
aMMC. The first region with amino acid sequence positions 1-14 
(region A) is near the N-terminal, the second region with sequence 
positions 71-136 (region B) is in the middle of the polypeptide, and 
the third region with sequence positions 195-222 (region C) is close 
to the C-terminal. 
Hopp and Woods (1981) have proposed a method of predicting 
the antigenic determinants of a protein from its amino acid sequence. 
The method is based on the assumption that the region of antigenic 
determinant is the region with greatest local hydrophilicity. In this 
� 
method, each amino acid residue is assigned with a numerical value 
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(hydrophilicity value). They found that the point of highest local 
average hydrophilicity is invariably located in, or immediately 
adjacent to，an antigenic determinant. The Hopp plot of aMMC is 
illustrated in Fig. 5.1 
� 
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Fig. 5.1 Plot ofhydrophilicity index of amino acid residues of aMMC 
according to the method ofHopp and Woods (1981). Three 
separate regions (A，B and C) were found to be immuno-reactive 
in our study. 
� 
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In the figure, it can be seen that the three antigenic regions 
found in our study are all hydrophilic. However, some regions with 
substantial hydrophilicity are not revealed from the immuno-
screening，suggesting that hydrophilicity is not the only factor 
affecting antigenicity. It appears that antigenic regions are all 
hydrophilic, but hydrophilic regions are not necessarily antigenic. 
Van Regenmortel et al. (1986) have determined the antigenic activity 
of six short peptides corresponding to accessible regions (hydrophilic 
regions) of tobacco mosaic protein and found that all these peptides 
possess no antigenic activity. They also discovered that more and 
more antigenic determinants are found in more structured regions of 
the protein，e.g. helices. In this case the longer peptide may be 
folding up in solution to mimic part of the native structure. Hence, a 
local conformational requirement is important to the formation of an 
antigenic region. In this respect, a large area of accessibility is 
required in addion to hydrophilicity. 
As the 3-dimensional structure of aMMC is known and a 
molecular model of aMMC has been proposed (Dong, 1993)，the 
sequences of the epitopic regions of aMMC can be analysed with this 
� 
model. The analysis was performed on a Silicon Graphics 
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Workstation using a set of X-ray diffraction data of aMMC. A 
schematic representation of the spatial distribution of the antigenic 
determining regions as mapped out by our immunological screening 
















Fig. 5.2 Spatial distribution of the antigenic regions of aMMC. 
Three immunogenic regions are shown in different colours. 
It can be seen that the immunogenic region B is located 
at the opening of the cleft believed to be crucial in ribosome 
inactivation. The important residue Glu-160 at the bottom 
of the cleft is indicated as a reference. 
� 
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It can be seen that all the three antigenic regions are located on 
the surface of the molecule. The largest epitopic region B as evident 
by the high frequency of immuno-reactive fragments obtained in the 
library screening, is found to have a wide area of accessibility on the 
molecule surface. This region contains an obvious a-helix structure 
in sequence positions 112 to 121 (ERLQIAAGKP). Region A is 
located at the N-terminal and region C near the C-terminal and both 
of them are surface accessible. 
Since the immuno-reactive regions are always the most 
accessible regions to other molecules, it is of interest to correlate the 
structural topology of a protein molecule with its antibody binding 
regions. From the sequence of the aMMC cDNA, it is found that 
natural aMMC is expressed with a signal peptide. The signal peptide 
consists 23 amino acid residues and is essentially hydrophobic. The 
function of the signal peptide is found to be important in protein 
targeting (von Heijne，1986). However, this signal peptide has to be 
cleaved before the mature protein is formed. In our study, region A 
joins directly with the signal sequence in the nascent protein. It can 
be speculated that this region may also serve as a cleavage point 
�� 
between the signal sequence and the mature peptide by pulling the 
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cleavage site onto the surface of the molecule. 
A mechanism for ribosome-inactivation by TCS has been 
proposed by Zhang and Liu (1992). An RNA N-glycosidase activity 
of TCS is presumably involved in the hydrolysis of the 28S rRNA. 
Some important amino acid residues involved in this reaction have 
been reviewed in the Introduction. These residues are believed to be 
located in an active-site cleft of aMMC. Dong (1993) has calculated 
the distances between these amino acids and the corresponding groups 
on the 28S rRNA molecule in the aMMC-rRNA complex (Table 5.1). 
A graphical presentation of the interaction between these amino acids 
and the rRNA substrate is shown in Fig. 5.3. 
Residue on ceMMC Group Residue on 28S rRNA Position Distance (A) 
Glu-160 OEl CI 4324 2.84 
Arg-163 NHl N9 4324 3.17 
Arg-122 NHl 02P 4323 3.15 
Asn-190 ND2 02P 4323 2.95 
Asn-190 ND2 OIP 4323 2.79 
Tyr-111 N OIP 4324 3.28 
Ser-193 N OIP 4325 2.74 
Tyr-70 OH 02P 4325 2.96 
Glu-189 O 2 OH 4324 2.71 
Table 5.1 Interaction of aMMC with 28S rRNA (Dong, 1993) 
� 
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Fig. 5.3 Interaction of 28S rRNA (blue) with aMMC (red). 
This model was created by the computer software QUANTA 
(Polygene, USA) based on the coordinate information of aMMC 
and 28S rRNA. Dotted lines represent hydrogen bonds. Some 
amino acid residues involved are shown. Tyr-111 and Arg-122 
were found in region B in our study. The N-glycosidic cleavage 
point of 28 S rRNA is indicated by an arrow. 
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Based on the 3-D model of interaction between aMMC and 
28S rRNA, the antigenic region B was found to be located at the 
opening of the active-site cleft. This antigenic region is close to the 
activity area responsible for ribosome inactivation. Some residues in 
the antigenic regions (Tyr-111 and Arg-122) are noted to be also 
involved in the biological activity. Since this area can elicit strong 
epitopic response in our study, it is likely that antibodies raised 
against aMMC may be able to inhibit or block the ribosome 
inactivation property of the protein. In our study, the monoclonal 
aMMC antibody #A1 was found to inhibit the ribosome-inactivating 
activity of aMMC. Since this antibody specifically reacts with the 
clone 401, and the clone 401 represents an immuno-reactive region 
(Region B) close to the proposed active site of aMMC, suggesting 
that region B plays an important role in this biological property. 
Another epitopic fragment of aMMC was discovered in the C-
terminal region. This fragment has a 6-sheet structure and is also 
found exposed on the surface of the molecule. As can be seen in the 
molecular model, it is quite distant from the active site cleft and 
seems to be specific for aMMC. Unlike the N-terminal sequence, the 
C-terminal sequence of most RIPs is much less conserved. This may 
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be due to their less importance in supporting the molecular structure 
for biological functions. Antigenicities of this region are therefore 
more species-specific. 
In our study, a chimeric protein from aMMC and TCS was 
constructed. It is of interest that the anti-TCS serum 87047 was not 
able to recognize this hybrid molecule although the N- and C-terminal 
sequence of the protein was present. This suggests that the TCS-
specific epitopes recognized by antiserum 87047 are not present in 
this protein. In contrast, this chimeric protein could be recognized by 
the two anti-aMMC sera RB004 and RB006. Since only the middle 
region of the chimeric protein was replaced by aMMC, the epitopes 
revealed by these antisera are likely present on this middle sequence. 
The inability of the anti-TCS serum to recognize the chimeric 
molecule suggests that the C- and N-terminal portions of TCS are less 




The epitopic regions of aMMC have been determined. The 
results of this study may lead to a more logical design of an aMMC 
molecule with less antigencity but reasonable biological activity. In 
most cases，the availability of a 3-dimensional structure of a protein 
is essential in the analysis of the functional fragments of the whole 
molecule. The use of fusion proteins to identify sequence-specific 
antibodies has proven to be an efficient way to map out antigenic 
determining regions of a protein. The generalization of this approach 
may help to explore the immunological properties of the RIPs. In our 
study, three epitopic regions on the aMMC surface were found. 
These regions can be modified or replaced with residues of less 
antigenicities so that a less antigenic aMMC can be made. Since one 
of the epitopes was found near the active site cleft，it would be of 
interest to see if a highly specific antibody directed against this region 
would block RIP activity. In this way, the antigenicity and biological 
activity of an RIP can be correlated. This type of study would best 
be performed by a set of monoclonal antibodies. A preliminary study 
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APPENDIXES GENERAL PROCEDURES 
A.1 DNA SEQUENCING 
Denaturation of Double Stranded Template 
Plasmid DNAs were purified using MagicPrep from Promega 
(Australia). In a microfuge tube, 8 |LI1 of the plasmid DNA (1.5-2 |Lig) 
were mixed with 2 |LI1 of 2 M NaOH. The mixture was incubated at 
room temperature for 10 min. After incubation, 3 |LI1 of 3 M sodium 
acetate (pH 4.8)，7 |LI1 of distilled water and 60 |LI1 of absolute ethanol 
were then added and vortex mixed. The tube was put in a -70°C 
freezer for 30 min. The precipitated DNA was collected by 
centrifugation at 15,000 xg for 15 min at room temperature. The 
pellet was washed with 60 |LI1 of ice-cold 70% ethanol and dried 
under vaccum briefly, and dissolved in 10 |J1 of distilled water. 
Annealing Reaction 
To 10 |LI1 of the denatured template from the above, 2 |il of 
Annealing Buffer and 2 |xl of primer solution (0.05-0.1 |Lig) were 
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added. The mixture was incubated at 37°C for 20 min for annealing. 
After incubation, the tube was placed at room temp for 10 min, then 
centrifuged breifly. If sequencing was not performed in the same day, 
the solution was stored at -20°C until use. 
Sequencing Mixes 
A set of microfuge tubes labelled A, C, G and T，respectively, were 
used. To each corresponding tube 2.5 |il of either A-Mix-Short, C-
Mix-Short, G-Mix-Short or T-Mix-Short were added. The tubes were 
capped and placed at room temperature until use. 
Enzyme Premix 
T7 DNA polymerase was diluted to about 1.5 U/|LI1 using Enzyme 
Dilution Buffer. The enzyme solution was kept on ice until use. 
In a microfuge tube, 3 |LI1 of Labeling Mix-dCTP, 2 of diluted 
T7 DNA polymerase, 1 i^l of distilled water，and 1 |LI1 of S35-dCTP 
(10 |iCi/|al) were mixed. The components were collected to the tube 
� 
bottom by brief centrifugation. 
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Labelling Reaction 
To the tube containing the annealed template and primer, 6 |LI1 of 
Enzyme Premix was added, mixed with a pipet tip, and collected by 
brief centri&gation. The content was incubated at room temperature 
for 5 min. 
Termination Reaction 
4.5 |LIL of the 5-min incubation mixture was transferred into each 
of the 4 sequencing mixes pre-warmed at 37°C. The mixture was 
incubated at 37°C for 5 min. 5 |LI1 of Stop Solution was added. The 
solution was stored at until use. Before gel loading, 3 |LI1 
aliquots from each sample were heated at 80°C for 3 min, and placed 
on ice immediately. 
Electrophoresis 
Sequencing electrophoresis was carried out with the Pharmacia 
2010 MultiPhor system. Preparation of reagents and treatment of the 
�� 
glass plates were performed according to the manufacturer's 
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instructions. 
Preparation of 6% polvacrvlamide gel 
A gel mix was prepared by dissolving 14.5 ml 40% acrylamide, 10 
ml lOx TBE buffer, 42 g urea in 100 ml of distilled water. The mix 
was filtered through a 0.45-|Lim membrane and was degassed for 15 
min under vaccum. 
Bind and Repel-silane treatment of glass plates 
The glass plates to be used for setting sequencing gel were cleaned 
with ethanol. The cover plate was treated and polished with Bind-
silane solution (4 ml EtOH, 1 ml acetic acid, 15 |LI1 Bind-silane), and 
the thermostatic plate was treated and polished by Repel-silane 
solution. 
Electrophoresis 
Polyacrylamide gel was pre-run at 1500 V for 30 min before the 
�� 
samples were loaded. Sequencing samples were loaded and run at 
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1800 V for 2.5 hr at 55°C. Three |LI1 of sample per lane was used. 
Fixing 
After electrophoresis, the cover glass plate with the gel bound on 
it was carefully separated from the thermostatic plate by tilting at the 
comer with a piece of spatula. The gel was fixed for 10 min each in 
the first and second fixing solution, then washed for 1 hr with 
running water and dried thoroughly by putting in a 80°C oven for 1 
hr. 
Autoradiography 
After drying, the sequencing gel was covered with a sheet of 
Kodak X-OMAT film and exposed for 5 days in a dark room. The 
film was then developed for 5 min in the Kodak X-ray film developer 
and fixed for 5 min in the Kodak X-ray film fixer. 
� 
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A.2 PURIFICATION OF DNA WITH GENE CLEAN 
Gene Clean is a Trade Mark of Bio 101 (USA). Agarose gel after 
electrophoresis was cut into pieces with a scalpel and transferred to 
a microfuge tube. The gel was weighed and mixed with 2.5 volumes 
(w/v) of Nal reagent (Bio 101). The tube was incubated at 50°C for 
2 min or until the gel was completely dissolved. Then 5 |LI1 of 
Glassmilk (Bio 101，shake well before use) were added and shaken. 
The tube was centrifuged for 10 sec and the pelleted Glassmilk was 
washed 3 times with 200 |LI1 New Wash solution (Bio 101) by mixing 
and centrifugation. The pellet from the last wash was suspended in 10 
|Lil of distilled water or TE (pH 8.0). 
I' 
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A.3 PURIFICATION OF DNA PRIMERS AFTER SYNTHESIS 
Manual Deprotection 
The DNA synthesis cartridge after synthesis was unpluged from the 
synthsizer and connected to a 1-ml syringe with a male-to-male luer. 
A minimum volume of ammonium hydroxide was drawn up into the 
syringe. The syringe was fixed by inserting verically into a rubber 
stopper and incubated at room temperature for 15 min. Then the 
ammonia solution wasa expelled into a reservoir vial which could 
withstand pressure and resist ammonia, eg. Wheaton serum bottle 
240408). The ammonia treatment was then repeated 3 more times for 
15 min each. 
The volume of the DNA solution obtained was brought to 3 ml with 
conc NH4OH and incubated at 55°C for 8 to 15 hr. DNA after this 
treatment was stored at 4°C for further OPC purification. 
OPC Purification 
A 1-ml aliquot of the above was diluted with 3 ml of distilled 
water. The rest (2 ml) was stored at -20'^ C for further use. An OPC 
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column (ABI) was set up according to manufacturer's instructions and 
flushed with 5 ml HPLC grade acetonitrile and 5 ml 2.0 M 
triethylamine acetate, respectively. Then 4 ml of crude DNA solution 
were loaded into the syringe and pushed through the column. The 
eluate was saved and reloaded one more time. The column was 
flushed with 3x5 ml dil ammonium hydroxide and 2x5 ml distilled 
water, detritylated with 5 ml 2% trifluoroacetic acid，and washed with 
2x5 ml distilled water. The purified oligo was eluted by flushing with 
1 ml 20% acetonitrile. An aliquot of the eluate was taken to 
evaporate to drynessand dissolved in water to determine the optical 
density at 254 nm. The purified oligo primer was stored in TE (pH 
8.0) at -20�C. 
< 
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A.4 PURIFICATION OF PLASMID DNA BY 
MAGIC PREP (PROMEGA) 
The bacterial pellet from a 1.5-ml overnight culture after 
centrifiigation was suspended in 200 |LI1 of Cell Suspension Solution 
(50 mM Tris-HCl pH 7.5, 10 mM EDTA,100 [ig/mL RNase A) in a 
microfuge tube. 200 |LIL of Cell Lysis Solution (0.2 M NaOH，1% 
SDS) were added and mixed by inverting several times. Then 200 |al 
of Neutralization Solution (2.55 M potassium acetate pH 4.8) were 
mixed by inverting. The tube was centrifuged 5 min at 13000 xg in 
a microcentrifuge, and the supernatant was transferred to a new 
microfuge tube. 1 ml of Magic MiniPreps DNA Purification Resin 
(Promega) was added to the supernatant and mixed mix by inverting. 
For each MiniPrep one Magic MiniPreps mini-column was used. A 
3-ml syringe barrel was attached to the luer-lok extention of each 
column. The DNA Purification Resin containing the bound DNA was 
decanted into the syringe. The mini-column was washed with 2 ml of 
diluted Column Wash Solution (200 mM NaCl, 20 mM Tris-HCl pH 
7.5, 5 mM EDTA; diluted 1:1 with absolute EtOH). Then the syringe 
was removed and the mini-column was transferred to a microfuge 
� 
tube. The plasmid DNA was eluted by adding 50 of water of TE 
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(pH 8.0) preheated at 65-70°C and spinned in a microfUge tube for 
20 sec. Plasmid DNA obtained was stored at 4 � C or -20°C. 
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A.5 LARGE-SCALE PREPARATION OF PLASMID DNA BY 
QIAGEN 
150 ml of an overnight bacterial culture were centrifuged at 5000 
rpm for 10 min at 4°C. The pellet was suspended in 4 ml of Buffer 
PI (100 |Lig/ml RNase A in 50 mM Tris-Cl，10 mM EDTA pH 8.0). 
The suspension was transferred to a 50-ml centrifiige tube. 4 ml of 
Buffer P2 (200 mM NaOH, 1% SDS) were added and mixed gently. 
The mixture was incubated at room temp for 5 min. Then 4 ml of 
Buffer P3 (2.55 M Potassium acetate pH 4.8) were added and mixed 
immediately but gently. The suspension was centririfuged at 15000 
rpm for 30 min at 4°C. After centrifugation, the supernatant was 
removed promptly. Meanwhile, a Qiagen-100 column was 
equilibrated 2 ml of Buffer QB (750 mM NaCl, 50 mM MOPS, 15% 
ethanol pH 7.0). The supernatant after centrifiigation was applied to 
the column and reloaded 2 times. The loading, the column was 
washed with 2x4 ml of Buffer QC (1.0 M NaCl, 50 mM MOPS, 15% 
ethanol pH 7.0). The DNA was eluted with 2 ml of Buffer QF (1.2 
M NaCl, 50 mM MOPS, 15% ethanol pH 8.0) and precipitated with 
0.5 volume of isopropanol at room temp. The tube was then 
�� 
centrifuged for at 13000 xg 10 min at 4°C, and washed with 300 |LI1 
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70% ethanol. 
The DNA was dried briefly and dissolved in 200 |LI1 of TE, pH 8.0 
(final concentration approximately 0.5 |Lig/|Lil) 
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A.6 LOWRY PROTEIN DETERMINATION 
The assay was according to the method of Lowry (1952). For assay 
of protein concentrations, 0.2 ml aliquots of protein samples were 
mixed with 2 ml of Reagent A (2 ml of 2% CUSO4.5H2O, 2 ml of 4% 
KNa-tartrate, 96 ml of 3% NazCO? in 0.1 M NaOH). The mixture was 
incubated at room temperature for 10 min. Then 0.2 ml of Reagent 
B (1:1 dilution of Phenol-Ciocalteau Reagent in water) was added and 
incubated for 40 min at room temperature. Protein concentrations 
were read at OD 660 nm against a standard curve with serial dilutions 
of BSA of 0.4 mg/ml following the same procedure. 
� 
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A.7 PREPARATION OF ACID PHENOL 
50 g of liquid phenol were mixed with 50 ml of 50 mM Sodium 
Acetate (pH 4.00). The suspension was let stand at room temperature 
for 1 hr and the upper layer (aqueous phase) was removed. Then 
another 50 ml of 50 mM Sodium Acetate (pH 4.00) were added and 
stirred to emulsify. The suspension was let stand again to separate. 
An aliquot of the aqueous phase was taken to check pH. Extraction 
was repeated until pH of the aqueous phase was lower than 4.1. 
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A.8 SDS-POLYACRYLAMIDE GEL ELECTROPHORESIS 
Reagents 
Solution A (30% Acrvlamide. 0.8% BIS) 
Acrylamide 60 g 
N,N'-methylene-bis-acrylamide 1.6 g 
Water to 200 ml. Store in dark at 4°C. 
Solution B fl.5M Tris. DH 8.8) 
Tris 36.34 g 
Adjust pH to 8.8 with 1 N HCl (will need about 78 ml). 
Water to 200 ml. 
Store in cold. Check pH if stored over several months. 
Solution C (\0% SDS) 
10% SDS (w/v) 
Solution D (0.5M Tris. DH 6.8) 
Tris 6.04 g 
Adjust pH to 6.8 with 1 N HCl (will need about 43 ml). 
Water to 100 ml. Store in cold. Check pH periodically. 
Ix Running buffer: Tris-glvcine-SDS (pH 8.6) 
Tris 6.0 g 
Glycine 28.8 g 
SDS 2.0 g 
Water to 2000 ml. 
2x SDS Gel-loading buffer 
� 
Solution D 1.25 ml 
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Solution C 1.0 ml 
2-Mercaptoethanol 0.1 ml 
Glycerol 1.0 ml 
0.1% Bromophenol blue 0.2 ml 
Water to 5 ml 
Gel Staining Solution 
Coomassie blue (final 0.25%) 7.5 g 
Absolute methanol 1362 ml 
Glacial acetic acid 276 ml 
Water to 1362 ml 
Gel Destain Solution 
Acetic acid 160 ml 
Ethanol 500 ml 
H2O to 2000 ml 
Preparation of Acrvlamide Gels 
(For 2 gels run on Bio-Rad Protean II mini gel tank) 
Running Gel 
Gel concentration 4% 5% 7.5% 10% 12.5% 15% 
‘ Solution A (ml) 1.1 1.3 2.0 2.6 3.3 4.0 
Solution B (ml) 2.0 2.0 2.0 2.0 2.0 2.0 
Solution C 80 80 /xl 80 /xl 80 ill 80 fil 80 fil 
Distilled HjO (ml) 4.8 4.6 3.8 3.4 2.5 1.9 
TEMED 8 1x1 8 /il 6 fil 6 /il 6 /xl 6 fil 
Ammonium 80 pil 80 /xl 80 /xl 40 /xl 40 /xl 40 fxl 
persulfate 
(100 mg/ml) 
2% Spacer Gel 
Solution A 0.8 ml 
Solution D 2.0 ml � 
Solution C 80 i^l 
239 
Distilled 即 5.2 ml 
TEMED 8 i^l 
10% APS 80 >il 
Electrophoresis 
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